--
-- Host: 115.28.66.83    Database: gn
-- ------------------------------------------------------


--
-- Table structure for table `PUBMED`
--

CREATE TABLE `PUBMED` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `title` varchar(1000) DEFAULT NULL,
  `journal` varchar(1000) DEFAULT NULL,
  `score` varchar(10) DEFAULT NULL,
  `pdata` varchar(100) DEFAULT NULL,
  `author` varchar(1000) DEFAULT NULL,
  `country` varchar(100) DEFAULT NULL,
  `center` varchar(100) DEFAULT NULL,
  `species` varchar(200) DEFAULT NULL,
  `pnumber` varchar(10) DEFAULT NULL,
  `ckd` varchar(100) DEFAULT NULL,
  `ns` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `PUBMED`
--



--
-- Table structure for table `cli`
--

CREATE TABLE `cli` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `indicator` varchar(100) DEFAULT NULL,
  `moltype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `cli`
--

INSERT INTO `cli` VALUES (0,'11967037','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(160)','2.0 g/day ','H:L','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','HR','3.671(2.19,6.16)','univariate','N','＜0.0001','cox','worse\r'),(70000002,'12172761','Grade of proteinuria ','proteinuria ','other','urine','not mention','not mention','IgAN(79)','1.0 g/1.73 m2 per day,3.0 g/1.73 m2 per day','H:M:L','ESRD','N','HR','2.99(1.56–5.73)','multivariate','ACE genotype ','0.001','cox','worse\r'),(70000003,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','other','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','ESRF','N','HR','1.13','multivariate','age0,gender male,CrCl0,MAP0,race','<0.001 ','cox','worse\r'),(70000004,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','other','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','ESRF','N','HR','1.2','univariate','N','<0.001 ','cox','worse\r'),(70000005,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','other','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','N','less negative slope CrCl ','β','-0.39','univariate','N','<0.001 ','linear','worse\r'),(70000006,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','other','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','N','less negative slope CrCl ','β','-0.33','multivariate','age0,gender male,CrCl0,MAP0,race','<0.001 ','linear','worse\r'),(70000007,'12897092','creatinine clearance (CrCl0) ','creatinine','other','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','ESRF','N','HR','0.96','univariate','N','<0.001 ','cox','better\r'),(70000008,'12897092','creatinine clearance (CrCl0) ','creatinine','other','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','ESRF','N','HR','0.96','multivariate','age0,gender male,UP0,MAP0,race','<0.001 ','cox','better\r'),(70000009,'12897092','creatinine clearance (CrCl0) ','creatinine','other','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','N','less negative slope CrCl ','β','0.18','univariate','N','<0.001 ','linear','better\r'),(70000010,'12897092','creatinine clearance (CrCl0) ','creatinine','other','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','N','less negative slope CrCl ','β','0.11','multivariate','age0,gender male,UP0,MAP0,race','0.03','linear','better\r'),(70000011,'11961402','duration of proteinuria ','proteinuria ','other','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(57)','N','N','N','Ccr ','r','-0.354','univariate','N','0.0069. ','Parametric linear regression analysis ','worse\r'),(70000012,'12164881','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(137)','2g/day','H:L','doubling of Scr or initiation of hemodialysis','N','HR','28.3(7.3-109.8)','multivariate','hypertention at renal biopsy,AGT C(-20)','<0.001 ','cox','worse\r'),(70000013,'12566518','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(216)','the amount of Proteinuria','＞3000mg/day:＜1000mg/day','doubling the baseline serum creatinine ','N','HR','4.0(1.8-8.5)','univariate','N','0.0004','cox','worse\r'),(70000014,'12566518','Creatinine ','creatinine','other','serum ','not mention','not mention','IgAN(216)','1.4 mg/dl ','H:L','doubling the baseline serum creatinine ','N','HR','3.6(1.9-5.8)','univariate','N','0.0015','cox','worse\r'),(70000015,'12746403','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(271)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','3.362(1.891-5.977)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','<0.0001 ','cox','worse\r'),(70000016,'12746403','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[female](143)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','2.505(1.203-5.217)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','0.0141','cox','worse\r'),(70000017,'12746403','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[male](128)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','4.768(1.664-13.666)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','0.0036','cox','worse\r'),(70000018,'12885793','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(276)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.40(1.91-6.05)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','<0.0001 ','cox','worse\r'),(70000019,'12885793','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[carrying the ACE II genotype](106)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.54(1.08-3.25)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','0.026','cox','worse\r'),(70000020,'12885793','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[carrying the ACE ID/DD genotype](170)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','5.08(1.90-13.57)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','0.0012','cox','worse\r'),(70000021,'14616762','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(225)','1.0g/day','H:L','ESRD(when patients underwent first hemodialysis)','N','HR','3.004(1.655-5.454)','multivariate','hypertension at the time of renal biopsy ','0.0003','cox','worse\r'),(70000022,'14684698','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(267)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','2.961(1.719-5.101)','univariate','N','＜0.0001','cox','worse\r'),(70000023,'14684698','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(267)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.102(1.771-5.433)','multivariate','\"Hypertension,No administration',NULL,NULL,NULL),(70000024,'14684698','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[with the AA genotype of ACE A2350G](87)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','2.620(1.209-5.680)','univariate','N','0.0147','cox','worse\r'),(70000025,'14684698','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[with the AG or GG genotype of ACE A2350G](180)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.307(1.412-7.743)','univariate','N','0.0059','cox','worse\r'),(70000026,'15609695','IgA/C3 ratio','IgA/C3','other','blood','not mention','measure serum IgA and C3 using a turbidimetric immunoassay and then calculate','IgAN(86)','4.5','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.05','log-rank test ','worse\r'),(70000027,'16105038','protein ','proteinuria ','other','urine','not mention','not mention','IgAN[whose serum creatinine concentrations were normal at the time of renal biopsy](142)','1.0g/day','H:L','100% increase in serum creatinine from baseline ','N','RR','4.20(1.14–15.56)','multivariate','Gender,Age,Serum creatinine,Hypertension,Glomerulosclerosis ,Mesangial proliferation,Area of fibrosis,a-smooth muscle actin+ area,Fibroblast-specific protein 1+ cells','0.032','cox','worse\r'),(70000028,'16175941','protein ','proteinuria ','other','urine','not mention','not mention','IgAN(181)','according to urinary protein excretion: ','isolated hematuria:hema- turia with proteinuria < 1 g/24 hours: hema- turia with proteinuria > 1 g/2','N','Cumulative risk of persistent hematuria and/or proteinuria ','Kaplan-Meier ','N','univariate','N','＜0.05','log-rank test ','worse\r'),(70000029,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','other','urine','not mention','sandwich-ELISA','IgAN(132)','tertile','1st:2nd:3rd','ESRD and/or doubling of sCr.','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','better\r'),(70000030,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','other','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.93 (0.90–0.96)','univariate','N','＜0.0001','cox','better\r'),(70000031,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','other','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.94 (0.91–0.98)','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.002','cox','better\r'),(70000032,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','other','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','ROC','0.91 (95% CI: 0.84–0.95)',' ','','','','\r'),(70000033,'18334740','mast cells','mast cells','other','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','serum creatinine at the time of biopsy ','r','0.295','univariate','N','0.0201','Spearman’s correlation coefficient ','worse\r'),(70000034,'18334740','mast cells','mast cells','other','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','serum creatinine at the end of follow-up ','r','0.323','univariate','N','0.0116','Spearman’s correlation coefficient ','worse\r'),(70000035,'18334740','mast cells','mast cells','other','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','clinical outcome of IgAN ','r','0.337','univariate','N','0.0077','Spearman’s correlation coefficient ','worse\r'),(70000036,'18334740','mast cells','mast cells','other','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','3.5 cells/mm2','H:L',' ESRD requiring dialysis or transplant','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r'),(70000037,'21490589','index of chronic damage (ICD) ','index of chronic damage (ICD) ','','','','','IgAN(93)','10%,30%','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r'),(70000038,'21490589','urinary albumin–creatinine ratio (ACR) ','proteinuria/creatinine','','','','','IgAN(93)','100300','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r'),(70000039,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','4.17(2.13 – 13.72)','univariate','N','not mention','logistic regression ','worse\r'),(70000040,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','3.15(1.68 – 10.79)','multivariate','age, gender, obese, smoke, hypertension, diabetes, ACEi/ARB, and corticosteroid treatment.','not mention','logistic regression ','worse\r'),(70000041,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','2.75(1.62 – 8.35)','univariate','N','not mention','logistic regression ','worse\r'),(70000042,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','1.46(1.20 – 6.59)','multivariate','age, gender, obese, smoke, hypertension, diabetes, ACEi/ARB, and corticosteroid treatment.','not mention','logistic regression ','worse\r'),(70000043,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','worse\r'),(70000044,'23391320','uric acid ','uric acid ','other','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','worse\r'),(70000045,'26894025','uric acid ','uric acid ','other','serum ','not mention','not mention','IgAN[follow-up for ≥1y,having complete laboratory data] (145)','serum uric acid level Z7.3 mg/dL in men and Z5.3 mg/dL in women, ','H:L','erum creatinine elevation above 1.2 mg/dL or over 20% elevation from baseline ','N','Kaplan-Meier ','N','univariate','N','＜0.0001','log-rank test ','worse\r'),(70000046,'25011573','averaged serum albumin (ALB)','averaged serum albumin','other','serum ','not mention','not mention','IgAN(369)','39g/L (ALB at month 6)','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.001','log-rank test ','better\r'),(70000047,'25011573','time-averaged serum albumin (TA-ALB) ','averaged serum albumin','other','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','better\r'),(70000048,'25011573','SCr','creatinine','other','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(70000049,'25011573','SCr ','creatinine','other','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(70000050,'25011573','SCr ','creatinine','other','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(70000051,'25011573','the time-averaged creatinine (TA-SCr) ','creatinine','other','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(70000052,'25011573','time-averaged serum albumin (TA-ALB) ','creatinine','other','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','0.8(0.70-0.93)','univariate','N','0.002','cox','better\r'),(70000053,'25011573','the time-averaged creatinine (TA-SCr) ','creatinine','other','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','1.02(1.01-1.03)','univariate','N','＜0.001','cox','worse\r'),(70000054,'25011573','time-averaged serum albumin (TA-ALB) ','creatinine','other','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','0.86(0.75-0.98)','multivariate','ALB(at baseline, at month 3,at month 6),TA-ALB,Scr(at baseline, at month 3,at month 6),TA-Scr,BUN(at baseline, at month 3,at month 6),TA-BUN,eGRF(at baseline, at month 3,at month 6),TA-eGFR,UPE,TA-UPE','0.002','cox','better\r'),(70000055,'15171553','Creatinine ','creatinine','other','serum ','not mention','not mention','IgAN(495)','133umol/L','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(70000056,'15171553','Creatinine ','creatinine','other','serum ','not mention','not mention','IgAN(495)','133umol/L','H:L','ESRD','N','HR','1.49(1.54-38.90)','multivariate','hypertension','0.01','cox','worse\r'),(70000057,'15171553','24h proteinuria','proteinuria ','other','urine','not mention','not mention','IgAN(495)','3g','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(70000058,'15458457','Urinary protein excretion ','proteinuria ','other','urine','not mention','not mention','IgAN(120)','N','N','N','∆Ccr ','r','0.71','univariate','N','<0.0001 ','linear','worse\r'),(70000059,'15458457','advanced oxidation protein prod- ucts (AOPP)','proteinuria ','other','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','N','N','N','∆Ccr ','r','0.53','univariate','N','<0.0001 ','linear','worse\r'),(70000060,'15458457','Urinary protein excretion ','proteinuria ','other','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','16.41 (3.97–67.84) ','univariate','N','0.00001','cox','worse\r'),(70000061,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','other','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.42 (1.28–1.58) ','univariate','N','0.00001','cox','worse\r'),(70000062,'15458457','Urinary protein excretion ','proteinuria ','other','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','7.78 (1.81–33.4) ','multivariate','Ccr,AOPP ','0.0057','cox','worse\r'),(70000063,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','other','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.11 (1.02–1.21) ','multivariate','Ccr ,Proteinuria ≥1 g/day yes','0.0305','cox','worse\r'),(70000064,'15458457','Urinary protein excretion ','proteinuria ','other','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','23.7 (5.35–104.8) ','multivariate','Hypertension,Angiotensin II inhibitors,AOPP ','0.0001','cox','worse\r'),(70000065,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','other','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.09 (1.00–1.18) ','multivariate','Hypertension,Angiotensin II inhibitors,Proteinuria ≥ 1g/day','0.042','cox','worse\r'),(70000066,'15458457','Urinary protein excretion ','proteinuria ','other','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','Kaplan-Meier ','N','univariate','N','< 0.00001','log-rank test ','worse\r'),(70000067,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','other','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','Kaplan-Meier ','N','univariate','N','< 0.0001 ','log-rank test ','worse\r'),(70000068,'16221102','proteinuria ','proteinuria ','other','urine','not mention','not mention','IgAN[ followed on average for 27 months after diagnosis and the creatinine clearance estimated by the Modification of Diet in Renal Disease formula was <85 mL/min] (229)','3.5g/day','H:L','ESRD','N','OR','3.456 (1.777–6.723) ','multivariate','Creatinine clearance,Hypertension,Sclerosed glomeruli,Interstitial fibrosis,Constant','0','logistic regression ','worse\r'),(70000069,'16221102','proteinuria ','proteinuria ','other','urine','not mention','not mention','IgAN[ followed on average for 27 months after diagnosis ] (347)','3.5g/day','H:L','ESRD','N','HR','1.962 (1.191–3.231) ','multivariate','Hypertension,Sclerosed glomeruli,Interstitial fibrosis','0.008','Cox ','worse\r'),(70000070,'24408121','Baseline proteinuria','proteinuria ','other','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.13 (1.07-1.18) ','univariate','N','＜0.001 ','Cox ','worse\r'),(70000071,'24408121','Proteinuria at month 6','proteinuria ','other','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.85 (1.64-2.09) ','univariate','N','＜0.001 ','Cox ','worse\r'),(70000072,'24408121','Proteinuria at month 6','proteinuria ','other','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.53 (1.27-1.84) ','multivariate','Age,Sex ,Haas classification,Baseline eGFR,Baseline proteinuria,Baseline SBP,SBP at month 6 ,Immunosuppressive therapy ,Uric acid','＜0.001 ','Cox ','worse\r'),(70000073,'24408121','TA(time average) proteinuria ','proteinuria ','other','urine','not mention','not mention','IgAN(703)','N','N','N','GFR ','Regression Coefficients','-0.21(\'-0.26 to\' -0.17)','univariate','N','＜0.001 ','linear regression ','worse\r'),(70000074,'24408121','TA(time average) proteinuria ','proteinuria ','other','urine','not mention','not mention','IgAN(703)','N','N','N','GFR ','Regression Coefficients','-0.21(\'-0.25 to\' -0.16)','multivariate','Age,Sex,Haas classification,Baseline eGFR ,Baseline proteinuria,TA proteinuria,Baseline MAP ,TA MAP,Immunosuppressive therapy ,Uric acid ','＜0.001 ','linear regression ','worse\r'),(70000075,'24824243','homocysteine ','homocysteine','other','serum ','not mention','Roche MODULAR automatic biochemistry analyzer ','IgAN(108)','with hyperhomocysteinemia  or not','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.005','log-rank test ','worse\r'),(70000076,'24824243','homocysteine ','homocysteine','other','serum ','not mention','Roche MODULAR automatic biochemistry analyzer ','IgAN(108)','with hyperhomocysteinemia  or not','H:L','ESRD','N','HR','4.71 (1.45-15.31) ','univariate','N','0.01','log-rank test ','worse\r'),(70000077,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','0.3,0.99','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','Kaplan-Meier ','N','univariate','N','＜0.001 ','log-rank test ','worse\r'),(70000078,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H/HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','Kaplan-Meier ','N','univariate','N','＜0.001 ','log-rank test ','worse\r'),(70000079,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','47.28 (6.38-350.15)','multivariate','Age,GFR,TA_MAP,Hypertension','＜0.001 ','Cox ','worse\r'),(70000080,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','406.35 (49.30-3349.18)','multivariate','Age,GFR,TA_MAP,Hypertension','＜0.001 ','Cox ','worse\r'),(70000081,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','26.59 (3.48-203.34)','multivariate','Age,GFR,TA_MAP,Hypertension,Pathologic findings','0.002','Cox ','worse\r'),(70000082,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','other','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','288.86 (34.03-2451.86) ','multivariate','Age,GFR,TA_MAP,Hypertension,Pathologic findings','＜0.001 ','Cox ','worse\r'),(70000083,'25355499','uric acid ','uric acid ','other','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','＞7.0 mg/dL for males and ＞6.0 mg/dL for females at the time of renal biopsy:H;uric acid level ≤6.9 mg/dL for males and ≤5.9 mg/dL for females:N','H:N','ESRD, defined as requiring dialysis or renal transplantation ','N','Kaplan-Meier ','N','univariate','N','0.0205','log-rank test ','worse\r'),(70000084,'25355499','uric acid ','uric acid ','other','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','N','N','ESRD, defined as requiring dialysis or renal transplantation ','N','HR','1.40(1.11–1.76)','univariate','N','0.0042','Cox ','worse\r'),(70000085,'25355499','uric acid ','uric acid ','other','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','N','N','ESRD, defined as requiring dialysis or renal transplantation ','N','HR','1.36(1.07–1.72)','multivariate','Male,Age,BMI,MAP,eGFR,Serum albumin,T-Cho,T-G,U-Prot,U-RBC,IgA/C3,Oxford classification ','0.011','Cox ','worse\r'),(70000086,'25700934','bilirubin ','bilirubin ','other','serum ','not mention','not mention','IgAN(694)','N','N','ESRD(initiation of renal replacement therapy, in- cluding hemodialysis, peritoneal dialysis and kidney transplantation)','N','HR','1.37 (1.22–1.53) ','multivariate','Age,sex','＜0.001 ','Cox ','worse\r'),(70000087,'25700934','bilirubin ','bilirubin ','other','serum ','not mention','not mention','IgAN(694)','N','N','ESRD(initiation of renal replacement therapy, in- cluding hemodialysis, peritoneal dialysis and kidney transplantation)','N','HR','1.18 (1.04–1.33) ','multivariate','age, sex and clinical parameters (serum albumin, urinary protein excretion, estimated glomerular filtration rate) and pathological parameters (mesangial hypercellularity score, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis)','0.001','Cox ','worse\r'),(70000088,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','Kaplan-Meier ','6.59','univariate','N','0.01','log-rank test ','worse\r'),(70000089,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','HR','3.25 (1.24 to 8.55)','univariate','N','0.02','cox','worse\r'),(70000090,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','HR','3.37 (1.13 to 10.09)','multivariate','Age,Sex,eGFR,24-h proteinuria,Albumin,NLR,Anti-nucleosome antibody,Anti-histone antibody,antimitochondrial antibody M2,Anti-cardiolipin antibody,Crescent formation,Fibrinoid necrosis,Glomerulosclerosis','0.03','cox','worse\r'),(70000091,'26704903','anti-CRP antibodies ','CRP antibodies','protein','Renal biopsy','not mention','in-house ELISA','LN[newly diagnosed LN patients and finish ] (24)','with orwithout','positive:negative','the time to response','N','Kaplan-Meier ','N','univariate','N','0.037','log-rank test ','worse\r'),(70000092,'22904352','IgG autoantibody ','IgG','protein','serum ','not mention','ELISA ','IgAN(97)','1.33 OD','H:L','dialysis or death ','N','Kaplan-Meier ','N','univariate','N','0.007','log-rank test ','worse\r'),(70000093,'22904352','IgA autoantibody ','IgA','protein','serum ','not mention','ELISA ','IgAN(97)','N','N','dialysis or death ','N','RR','1.22(1.02–1.44)','univariate','N','0.03','cox','worse\r'),(70000094,'22904352','IgG autoantibody ','IgG','protein','serum ','not mention','ELISA ','IgAN(97)','N','N','dialysis or death ','N','RR','2.77(1.59–4.81)','univariate','N','0.0003','cox','worse\r'),(70000095,'22752397','IgG ','IgG','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','Kaplan-Meier ','N','univariate','N','0.012','log-rank test ','worse\r'),(70000096,'22752397','IgG ','IgG','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','HR','0.35(0.14–0.82)','univariate','N','0.014','cox','worse\r'),(70000097,'22752397','IgG ','IgG','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','HR','0.31(0.12–0.77)','multivariate','Age,Female gender,Duration from onset ,History of hypertension ,Proteinuria,eGFR,Histological grade ,Use of RASI,Underwent ST','0.014','cox','worse\r'),(70000098,'25539484','complement 4 d','C4d','protein','serum ','not mention','measured by a turbidimetric method using a commercial kit in commercial equipment (Beckman Coulter IMMAGE, Fullerton, CA) following the instructions from the manufac- turer. ','IgAN(512)','16mg/dL','H:L','the serum creatinine increased 1.5 times from baseline.','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r'),(70000099,'25539484','complement 4 d','C4d','protein','serum ','not mention','measured by a turbidimetric method using a commercial kit in commercial equipment (Beckman Coulter IMMAGE, Fullerton, CA) following the instructions from the manufac- turer. ','IgAN(512)','16mg/dL','H:L','the serum creatinine increased 1.5 times from baseline.','N','HR','9.69 (1.90–49.48) ','multivariate','age, MAP, eGFR, 24h proteinuria, serum C3 level(binary variable, low C3 or not), serum C4 level (binary variable, low C4 or not), treatment (ACEI/ARB, steroid and/or immunosupressor) and pathological parameters based on Oxford IgAN classification including endocapillary hypercellularity, mesangial hypercellularity, interstitial fibrosis/ tubular atrophy, segmental glomerulosclerosis, crescents. ','0.03','cox','worse\r'),(70000100,'25031752','complement 4 d','C4d','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','Kaplan-Meier ','N','univariate','N','0.0072','log-rank test ','worse\r'),(70000101,'25031752','complement 4 d','C4d','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','OR','11.083','univariate','N','0.006','cox','worse\r'),(70000102,'25031752','complement 4 d','C4d','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','OR','15.022','multivariate','Age,Gender,Serum creatinine,eGFR,Hypertension,Proteinuria,Glomerulosclerosis,Mesangial hypercellularity,Interstisiel  brosis (%)','0.027','cox','worse\r'),(70000103,'24578331','complement 4 d','C4d','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(70000104,'24578331','complement 4 d','C4d','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','HR','4.65 (2.63-8.22) ','univariate','N','＜0.001','cox','worse\r'),(70000105,'24578331','complement 4 d','C4d','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','HR','2.45 (1.30-4.64) ','multivariate','Proteinuria,eGFR,Oxford classification','＜0.001','cox','worse\r'),(70000106,'18842673','C4d','C4d','protein','renal biopsy （Mesangial deposition）','not mention','inmunohistochemical staining ','IgAN(59)','degree of the Glomerular expression of α-SMA:>75% of the glomeruli were positive for C4d(positive) or ≤75% of the glomeruli were positive for C4d(negative) ','positive:negative','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0005','log-rank test ','worse\r'),(70000107,'20194446','anti-C1q antibody','C1q antibody','protein','serum','not mention','enzyme-linked immunosorbent assay (ELISA) kits ','LN(73)',' L:Patients with marked decrease of anti-C1q antibody levels (the extent of reduction exceeding 50% or being negative) at the end of the third month after treatment. H:Patients with persistent high levels or increased titers of anti-C1q antibody after treatment for 3 months.','H:L','disappearance of proteinuria','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(70000108,'20194446','anti-C1q antibody','C1q antibody','protein','serum','not mention','enzyme-linked immunosorbent assay (ELISA) kits ','LN(73)','N','N','disappearance of proteinuria','N','HR','0.229(0.103 to 0.513)','multivariate','ody levels at the end of the third month after treatment, and cyclophosphamide therapy ','<0.001','cox','worse\r'),(70000109,'23458172','Decreased eGFR at biopsy ','Decreased eGFR','other','blood','not mention','calculated using a modified MDRD formula for Chinese patients','IMN（217)',' 60 ml/min','decreased  eGFR：normal eGFR','N','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(70000110,'23458172','Decreased eGFR at biopsy ','Decreased eGFR','other','blood','not mention','calculated using a modified MDRD formula for Chinese patients','IMN（217)','N','N','N','N','HR','7.70（2.00-29.62）','multivariate','\"age, Hypertension,Proteinuria, Decreased eGFR,Elevated u-NAG, Elevated u-RBP,Existence of arteriole,pathological changes',NULL,NULL,NULL),(70000111,'23458172','chronic tubulointerstitial lesion','chronic tubulointerstitial lesion','other','renal biopsy ','not mention','grade of chronic tubulointerstitial lesions in cortex (classified according to the area of tubular at-rophy and the percentage of interstitial fibro-sis  as  Grade  1,  no  cortical  tubulointerstitia','IMN（217)','N','N','N','N','HR','2.90(1.37 – 6.16)','multivariate','\"age, Hypertension,Proteinuria, Decreased eGFR,Elevated u-NAG, Elevated u-RBP,Existence of arteriole,pathological changes,',NULL,NULL,NULL),(70000112,'25492250','IgG4','','protein','renal biopsy ','not mention','Immunohistological staining','PLA2R-related IMN（16）','the presence of dominant IgG4 deposition','Y:N','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','Kaplan-Meier ','N','univariate','N','0.032','log-rank test ','worse\r'),(70000113,'25492250','IgG4','','protein','renal biopsy ','not mention','Immunohistological staining','IMN（22）','the presence of dominant IgG4 deposition','Y:N','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','HR','0.02(0.00-0.91)','multivariate','age, sex, eGFR, relevance to PLA2R, IgG4 dominancy, treatment,uPCR,Enrenreich-Churg stage','0.044','Cox ','worse\r'),(70000114,'25492250','therapy','N','N','','N','N','IMN（22）','therapy','Immunosuppressive therapy: supportive therapy','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','HR','7.58(1.20-47.6)','multivariate','age, sex, eGFR, relevance to PLA2R, IgG4 dominancy, treatment,uPCR,Enrenreich-Churg stage','0.03','Cox ','better\r'),(70000115,'24886340','FE IgG','','protein','urine','not mention','immunoturbidimetry ','IMN（84）','0.02','H:L','progression to end stage kidney failure or kidney function (eGFR)decline ≥ 50% of baseline','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 95% and 59% ','AUC','worse\r'),(70000116,'24886340','FE IgG','','protein','urine','not mention','immunoturbidimetry ','IMN（70）','0.02','H:L','complete or partial remission of NS (proteinuria < 0.2 or < 2.0 g/day, respectively)','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 91% and 72%','AUC','worse\r'),(70000117,'24886340','FE IgG','','protein','urine','not mention','immunoturbidimetry ','IMN（84）','0.02','H:L','progression to end stage kidney failure or kidney function (eGFR)decline ≥ 50% of baseline','N','HR','20.84 (2.8 to 156.8) ','multivariate','age, kidney function, blood pressure, proteinuria, and treatment with ACEi/ARB,immunosuppression drug','0.003',' Cox ','worse\r'),(70000118,'24886340','FE IgG','','protein','urine','not mention','immunoturbidimetry ','IMN（84）','0.02','H:L','progression to end stage kidney failure or kidney function (eGFR)decline ≥ 50% of baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(70000119,'24886340','FE IgG','','protein','urine','not mention','immunoturbidimetry ','NS-IMN（343）','0.02','H:L','complete or partial remission of NS (proteinuria < 0.2 or < 2.0 g/day, respectively)','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(70000120,'15327418','remission','','other','other','not mention',' A PR was defined by a proteinuria value <3.5 g/day plus a 50% reduction from its peak value','IMN（343）','N','NR:PR:CR','Renal failure was defined as a CrCl ≤15 mL/min at last follow-up, the start of dialysis, or a renal transplantation','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','better\r'),(70000121,'15327418','partial remission','','other','other','not mention',' A PR was defined by a proteinuria value <3.5 g/day plus a 50% reduction from its peak value','IMN（343）','N','','Renal failure was defined as a CrCl ≤15 mL/min at last follow-up, the start of dialysis, or a renal transplantation','N','HR','0.08 (0.03–0.19)','multivariate','CrCl and proteinuria on set,follow-up MAP ,ACEi or ARB therapy','<0.001 ','Cox ','better\r'),(70000122,'21976738','IgG4','','protein','renal biopsy ','not mention','IHC','M-MN(8) and I-MN(42)','N','negative:positive','occurrence of malignancy','N','HR','0.065(0.007-0.051)','univariate','N','0.014','Cox ','better\r'),(70000123,'22995635','Maximal 24-h  proteinuria','','','','','','IMN(60）','7.2g','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','HR','1.127(1.011-1.053)','multivariate','cholesterol,albumin,eGFR,injury score,glomerular membrane thickness,glomerulopathy index,nephroangiosclerosis grade','0.008','COX','worse\r'),(70000124,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','','','IMN(60）','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','HR','1.029(1.007-1.051)','multivariate','cholesterol,albumin,eGFR,injury score,glomerular membrane thickness,glomerulopathy index,nephroangiosclerosis grade','0.01','COX','worse\r'),(70000125,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','','','IMN(60）','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','ROC','0.872','univariate','N','＜0.0001（The calculated sensitivity and specificity were respectively 91.67% and 77.08%)','AUC','worse\r'),(70000126,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','','','IMN(60）','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(70000127,'18308774','Uβ-NAG','Uβ-NAG','enzyme','urine','not mention','colourimetric assay','IMN（57）','2.64 U/mmol cr','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >137 µmol/l','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(70000128,'18308774','Uβ-NAG','Uβ-NAG','enzyme','urine','not mention','colourimetric assay','IMN（57）','2.64 U/mmol cr','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >137 µmol/l','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(70000129,'18308774','Uβ-NAG','Uβ-NAG','enzyme','urine','not mention','colourimetric assay','IMN（57）','2.50 U/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >138 µmol/l','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 74% and 81% for Uβ-NAG','AUC','worse\r'),(70000130,'18308774','Uβ-NAG','Uβ-NAG','enzyme','urine','not mention','colourimetric assay','IMN（57）','2.50 U/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >138 µmol/l','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 70% and 78% for Uβ-NAG','AUC','worse\r'),(70000131,'26893829','age','','','','','','IMN(73)','60 years','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','3.471','multivariate','age，tubulointerstitial injury area，BUN,SCr，eGFR','0.025','COX','worse\r'),(70000132,'26893829','serum albumin','','','','','','IMN(73)','25g/L','L:H','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','3.195','multivariate','Alb，tubulointerstitial injury area，BUN,SCr，eGFR','0.034','COX','worse\r'),(70000133,'26893829','tubulointerstitial injury area','','','','','','IMN(73)','0.25','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','6.724','multivariate','Alb，age，BUN,SCr，eGFR','0.044','COX','worse\r'),(70000134,'26893829','age','','','','','','IMN(73)','60 years','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.004','log-rank test ','worse\r'),(70000135,'26893829','serum albumin','','','','','','IMN(73)','25g/L','L:H','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.024','log-rank test ','worse\r'),(70000136,'26893829','tubulointerstitial injury area','','','','','','IMN(73)','0.25','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.001','log-rank test ','worse\r'),(70000137,'18495745','initial Cr','','','','','','MN(104)','','','ESRF','','HR','3.74(2.11-6.62)','univariate ','N','<0.001 ','COX','worse\r'),(70000138,'18495745','remission of proteinuria','','','','','','MN(104)','','','ESRF','','HR','0.39(0.21-0.72)','univariate ','N','0.002','COX','better\r'),(70000139,'18495745','age at biopsy','','','','','','MN(104)','','','death','','HR','1.1(1.02-1.19)','univariate ','N','0.008','COX','worse\r'),(70000140,'11961401','urRBP','','other','urine','not mention','not mention','GN(149)','1.0mg/l ','H:L','doubling of serum creatinine level','N','Kaplan-Meier ','N','univariate','N','0','log-rank test ','worse\r'),(70000141,'12401843','NAG excretion','','other','urine','not mention','For the determination of NAG in the second morning urine samples, a colourimetric assay was performed using 3-cresolsulfonphthaleyn-N-acetyl-b-Dglucosaminide which is hydrolysed by NAG with the releas','IMN(36)','18U/g urinary Cr','H:L','ESRD or doubling of sCr','N','\"Kaplan–',NULL,NULL,NULL,NULL,NULL,NULL),(70000142,'12401843','NAG excretion','','other','urine','not mention','For the determination of NAG in the second morning urine samples, a colourimetric assay was performed using 3-cresolsulfonphthaleyn-N-acetyl-b-Dglucosaminide which is hydrolysed by NAG with the releas','FSGS(20)','24 U/g urinary Cr','H:L','ESRD or doubling of sCr','N','\"Kaplan–',NULL,NULL,NULL,NULL,NULL,NULL),(70000143,'12552493','FE IgG','','other','urine','not mention','immunoglobulin G (IgG),and  1-microglobulin ( 1m) were measured in secondmorning urine samples by means of an immunonephelometric ethod on a BNA nephelometer (Behring, Milan, Italy) using rabbit serum','FSGS[with NS(50)]','0.140g/d','H:L','ESRF','N','Kaplan-Meier method，logistic regression','N','univariate','N','0','log-rank test ','worse\r'),(70000144,'17969486','FE β2m','','other','urine','not mention','immunonephelometry ','FSGS[untreated patients(9)]','0.01','H:L','not mention','N','ROC','0.571','univariate','N','＜0.05','log-rank test ','worse\r'),(70000145,'15563570','UIgG','UIgG','protein','urine','not mention','immunonephelometry','IMN（58）','250 mg/24 h','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  51%','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r'),(70000146,'15563570','UIgG','UIgG','protein','urine','not mention','immunonephelometry','IMN（58）','250 mg/24 h','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  51%','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 88% and 88% for UIgG','AUC','worse\r');

--
-- Table structure for table `epigenetics`
--

CREATE TABLE `epigenetics` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `originalname` varchar(1000) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `moltyep` varchar(500) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `epigenetics`
--

INSERT INTO `epigenetics` VALUES (50000001,'17913589','IgA1','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','IgA1','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78','L:H','ESRD','N','Kaplan','N','univariate ','N','0.0008','log-rank test ','worse\r'),(50000002,'17913589','IgA1','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','IgA1','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78,1.02','L:M:H','ESRD','N','Kaplan','N','univariate ','N','0.0032','log-rank test ','worse\r'),(50000003,'17913589','IgA1','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','IgA1','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78','L:H','ESRD','N','HR','3.7(1.54-8.90)','univariate ','N','0.004','cox','worse\r'),(50000004,'22673888','IgA1','galactose-deficient IgA1 ','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:3rd:2nd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','Kaplan','N','univariate ','N','0.004','log-rank test ','worse\r'),(50000005,'22673888','IgA1','galactose-deficient IgA1 ','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','4.03(1.36','univariate ','N','0.012','cox','worse\r'),(50000006,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.74 (1.28','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.016','cox','worse\r'),(50000007,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.72 (1.27','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.016','cox','worse\r'),(50000008,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.86 (1.33','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.013','cox','worse\r'),(50000009,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','6.76 (2.23','univariate ','N','0.001','cox','worse\r'),(50000010,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','5.18 (1.75','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.003','cox','worse\r'),(50000011,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','5.29 (1.78','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.003','cox','worse\r'),(50000012,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','4.76 (1.61','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.005','cox','worse\r'),(50000013,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','2.07 (1.53','univariate ','N','0.00000168','cox','worse\r'),(50000014,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.51 (1.16','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.002','cox','worse\r'),(50000015,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.50 (1.15','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.003','cox','worse\r'),(50000016,'22673888','IgA1','galactose-deficient IgA1 (Gd-IgA1)','IgA1','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.44 (1.11','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.006','cox','worse\r'),(50000017,'22673888','Gd-IgA1,IgA1 ','','Gd-IgA1,IgA1 ','','','','','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.42(1.15-2.12)','univariate ','N','0.021','cox','worse\r'),(50000018,'22673888','Gd-IgA1,IgA','','Gd-IgA1,IgA','','','','','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.56(1.05','univariate ','N','0.005','cox','worse\r');

--
-- Table structure for table `exp`
--

CREATE TABLE `exp` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `uniprot` varchar(100) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `descript` varchar(1000) DEFAULT NULL,
  `moltype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `exp`
--

INSERT INTO `exp` VALUES (0,'11744801','IFNα','P01563','IFNA2','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','serum Cr ','r','0.58','univariate','N','<0.001 ','correlation and linear regression;Pearson\'s correlation analyse','worse\r'),(2000002,'11744801','IFNα','P01563','IFNA2','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','CCr ','r','-0.478','univariate','N','＜0.01','correlation and linear regression;Pearson\'s correlation analyse','worse\r'),(2000003,'11744801','IFNα','P01563','IFNA2','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','BUN','r','0.405','univariate','N','＜0.03','correlation and linear regression;Pearson\'s correlation analyse','worse\r'),(2000004,'11744801','IFNα','P01563','IFNA2','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','s-β2MG','r','0.418','univariate','N','＜0.03','correlation and linear regression;Pearson\'s correlation analyse','worse\r'),(2000005,'11840384','CD44','P16070','CD44','CD44 antigen','protein','renal biopsy specimens ','tubulointerstitial compartment ','Immunohistochemistry ','IgAN(25)','N','N','N','degree of protein- uria ','r','0.642','univariate','N','＜0.01','Spearman rank correlation coefficient ','worse\r'),(2000006,'16105038','fibroblast-specific protein 1 (FSP1) ','P26447','S10A4','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Urinary excretion of protein for 24 hours','r','0.28','univariate','N','0.0005','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r'),(2000007,'16105038','fibroblast-specific protein 1 (FSP1) ','P26447','S10A4','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Serum creatinine','r','0.74','univariate','N','<0.0001','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r'),(2000008,'16105038','fibroblast-specific protein 1 (FSP1) ','P26447','S10A4','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Creatinine clearance ','r','−0.54','univariate','N','<0.0001','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r'),(2000009,'16105038','fibroblast-specific protein 1 (FSP1) ','P26447','S10A4','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN[whose serum creatinine concentrations were normal at the time of renal biopsy](142)','20 FSP1+ fibroblasts per HPF','H:L','100% increase in serum creatinine from baseline ','N','Kaplan-Meier ','N','univariate','N','< 0.0001','log-rank test ','worse\r'),(2000010,'17943082','EGF','P01133','EGF','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.95 (0.92–0.98)','univariate','N','0.002','cox','better\r'),(2000011,'17943082','EGF','P01133','EGF','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.95 (0.92–0.98)','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.002','cox','better\r'),(2000012,'17943082','MCP-1 ','P13500','CCL2','C-C motif chemokine 2','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','1.35 (1.04–1.80) ','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.024','cox','worse\r'),(2000013,'18334740','α-SMA','Q9BY41','HDAC8','Histone deacetylase 8','protein','renal biopsy （Glomerular）','not mention','Immunohistochemical','IgAN(62)','degree of the Glomerular expression of α-SMA:0/1(low) or 2/3/4(high)','H:L','ESRD requiring dialysis or transplant','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r'),(2000014,'19143943','EGF','P01133','EGF','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(33)','0.5pg/mgUcr','H:L','Progression of renal function ','N','Kaplan-Meier ','N','univariate','N','＜0.008','log-rank test ','better\r'),(2000015,'19143943','GADD45γ','O95257','GA45G','Growth arrest and DNA damage-inducible protein GADD45 gamma','protein','urine','not mention','2% agarose gel electrophoresis,ethidium bromide staining,PCR','IgAN(62)','positive or negative','positive:negative','an increase of 50% or more in serum creatinine concentration above baseline ','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r'),(2000016,'20649878','Nestin','P48681','NEST','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','quartiles','4th:1st','worsening renal function ','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r'),(2000017,'20649878','Nestin','P48681','NEST','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','degree of tubulointerstitial fibrosis','r','0.546','univariate','N','＜0.001','linear','worse\r'),(2000018,'20649878','Nestin','P48681','NEST','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','Serum creatinine ','r','0.51','univariate','N','0.001','linear','worse\r'),(2000019,'20649878','Nestin','P48681','NEST','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','eGFR ','r','-0.471','univariate','N','0.002','linear','worse\r'),(2000020,'20649878','Nestin','P48681','NEST','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','Urinary protein','r','0.329','univariate','N','0.036','linear','worse\r'),(2000021,'21402675','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','urine','not mention','sandwich-ELISA','IgAN[followed up for >12 months](107)','4.17 ng/mg urinary Cr','H:L','renal failure','N','Kaplan-Meier ','N','univariate','N','0.02','log-rank test ','worse\r'),(2000022,'21467131','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN[serum creatinine≤135umol/L](29)','1.7 ng/ min','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.045','log-rank test ','worse\r'),(2000023,'21467131','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN(65)','1.7 ng/ min','H:L','ESRD','N','HR','1.132 (1.035–1.238) ','univariate','N','not mention','cox','worse\r'),(2000024,'21467131','NGAL ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','urine','not mention','ELISA','IgAN(65)','47 ng/min','H:L','ESRD','N','HR','1.007 (1.002–1.012) ','univariate','N','not mention','cox','worse\r'),(2000025,'21467131','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN(65)','1.7 ng/ min','H:L','ESRD','N','HR','1.217 (1.087–1.302) ','multivariate','MAP,Serum albumin,Serum cholesterol,Serum creatinine,eGFR,Proteinuria,Urinary NGAL,Urinary α1m,Urinary β2m,Urinary IgG,Urinary albumin,Immunosuppressive therapy','not mention','cox','worse\r'),(2000026,'21490589','CD248','Q9HCU0','CD248','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','4.4%,9.8%','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r'),(2000027,'21490589','CD248','Q9HCU0','CD248','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','N','urinary albumin–creatinine ratio (ACR) ','β','0.329','multivariate','index of chronic damage,serum creatinine ','0.002','linear regression analysis ','worse\r'),(2000028,'21490589','CD248','Q9HCU0','CD248','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','N','eGFR ','β','-0.225','multivariate','urinary albumin–creatinine ratio (ACR) ,index of chronic damage','0.019','linear regression analysis ','worse\r'),(2000029,'21490589','CD248','Q9HCU0','CD248','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','ESRD','N','Exp(B) ','2.120 (1.428–3.146) ','univariate','N','＜0.0001','linear regression analysis ','worse\r'),(2000030,'21846944','NF-κB','P19838','NFKB1','Nuclear factor NF-kappa-B p105 subunit','protein','renal biopsies ','not mention','SWH','IgAN(62)','the score of NF-κB:0/1(low),2/3(high)','H;L','ESRD requiring dialysis or transplant.','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r'),(2000031,'21846944','NF-κB','P19838','NFKB1','Nuclear factor NF-kappa-B p105 subunit','protein','renal biopsies ','not mention','IHC','IgAN(62)','the score of NF-κB:0/1(low),2/3(high)','H;L','ESRD requiring dialysis or transplant.','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r'),(2000032,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000033,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','7.50 (3.40–16.54) ','univariate','N','＜0.001','cox','worse\r'),(2000034,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','4.81(2.17–10.70) ','multivariate','eGFR','＜0.001','cox','worse\r'),(2000035,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','7.02(3.00–16.48) ','multivariate','time average during  follow-up(TA) albuminuria','＜0.001','cox','worse\r'),(2000036,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','5.35(2.28–12.56) ','multivariate','time average during  follow-up(TA) albuminuria,eGFR','＜0.001','cox','worse\r'),(2000037,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','5.67(2.17–14.84) ','multivariate','time average during  follow-up(TA) albuminuria,eGFR,age','＜0.001','cox','worse\r'),(2000038,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.239(\'-0.384 to \'-0.094)','univariate','N','0.001','Linear regression ','worse\r'),(2000039,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.227(\'-0.376  to \'-0.079)','multivariate',' eGFR baseline','0.003','Linear regression ','worse\r'),(2000040,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.220(\'-0.365  to \'-0.074)','multivariate','time average during  follow-up(TA) MAP','0.003','Linear regression ','worse\r'),(2000041,'21940483','IL-2Ra ','P01589','IL2RA','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[with an estimated MDRD (Modifica- tion of Diet in Renal Disease) glomerular filtration rate (GFR) of  15 mL/ min/1.73m2 [chronic kidney disease (CKD) Stages 1–4 at baseline ](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.166(\'-0.310  to \'-0.022)','multivariate','time average during  follow-up(TA) albuminuria','0.024','Linear regression ','worse\r'),(2000042,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','N','time-averaged albuminuria (g/24 hr) ','Regression Coefficient ','0.26 (0.05–0.47) ','multivariate','age, sex, serum albumin, calcium, phosphate,PTH, 25(OH) vitamin D, baseline albuminuria, base- line eGFR, MAP, BMI, and the use of ACEIs or ARBs','0.02','Spearman rank test ','worse\r'),(2000043,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','entering CKD stage 5 or $50% reduction in eGFR ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000044,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','entering CKD stage 5 or $25% reduction in estimated GFR  within 10 years','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000045,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','12.53 (2.82–55.6) ','univariate','N','＜0.001','cox','worse\r'),(2000046,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','7.47 (1.60–35.01) ','multivariate','Baseline Albuminuria','0.01','cox','worse\r'),(2000047,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','5.49 (1.16–25.94) ','multivariate','albumin, phosphate, log parathyroid hormone','0.03','cox','worse\r'),(2000048,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','11.07 (4.67–26.21) ','univariate','N','＜0.001','cox','worse\r'),(2000049,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.70 (1.31–10.41) ','multivariate','Baseline eGFRa and MAP','0.01','cox','worse\r'),(2000050,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','7.52 (3.22–17.5) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r'),(2000051,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','4.07 (1.38–12.07)','multivariate','albumin, phosphate, log parathyroid hormone','＜0.001','cox','worse\r'),(2000052,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','8.59 (3.92–18.84) ','univariate','N','＜0.001','cox','worse\r'),(2000053,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.84 (1.50–9.82)','multivariate','Baseline eGFRa and MAP','0.005','cox','worse\r'),(2000054,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','6.13 (2.78–13.42) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r'),(2000055,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.68 (1.37–9.85)','multivariate','albumin, phosphate, log parathyroid hormone','0.01','cox','worse\r'),(2000056,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.05 (1.13–8.20)','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP]','0.03','cox','worse\r'),(2000057,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.92 (1.94–7.92) ','univariate','N','＜0.001','cox','worse\r'),(2000058,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.28 (1.06–4.90) ','multivariate','Baseline eGFRa and MAP','0.03','cox','worse\r'),(2000059,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.02 (1.41–6.50)','multivariate','Baseline Albuminuria','0.005','cox','worse\r'),(2000060,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.32 (1.09–4.94)','multivariate','entering CKD stage 5 or $50% reduction in estimated GFR ','0.03','cox','worse\r'),(2000061,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','4.58 (2.66–7.86) ','univariate','N','＜0.001','cox','worse\r'),(2000062,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.92 (1.55–5.53) ','multivariate','Baseline eGFRa and MAP','＜0.001','cox','worse\r'),(2000063,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.90 (2.22– 6.82) ','multivariate','Baseline Albuminuria ','＜0.001','cox','worse\r'),(2000064,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.74 (1.43–5.24) ','multivariate','albumin, phosphate, log parathyroid hormone ','0.002','cox','worse\r'),(2000065,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.94 (1.51–5.74) ','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP] ','0.002','cox','worse\r'),(2000066,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','4.21 (2.52–6.99) ','univariate','N','＜0.001','cox','worse\r'),(2000067,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.91 (1.61–5.27) ','multivariate','Baseline eGFRa and MAP','＜0.001','cox','worse\r'),(2000068,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.62 (2.14–6.12) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r'),(2000069,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.58 (1.40–4.76)','multivariate','albumin, phosphate, log parathyroid hormone ','0.002','cox','worse\r'),(2000070,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.88 (1.54–5.36) ','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP] ','＜0.001','cox','worse\r'),(2000071,'22383747','Fibroblast growth factor-23 (FGF23) ','Q9GZV9','FGF23','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','N','negative eGFR slope ','Regression Coefficient ','1.50 (0.40–2.60) ','multivariate','age, sex, serum albumin, baseline albuminuria, baseline estimated GFR, calcium, phosphate, parathyroid hormone, 25-hydroxyvitamin D, mean arterial BP, body mass index, and the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers ','0.008','Spearman rank test ','worse\r'),(2000072,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:2nd:1st:N','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000073,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:2nd:1st:N','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000074,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','28.65 (3.835-214.076)','univariate','N','0.001','cox','worse\r'),(2000075,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','9.47 (1.176 -76.315)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria','0.04','cox','worse\r'),(2000076,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','10.67 (1.129-100.770)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria,smoking, hypertension, diabetes, autoimmune disease, hepatitis B antigen, anti-hepatitis C antibody, and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or steroids','0.04','cox','worse\r'),(2000077,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','11.97 (3.591-39.871)','univariate','N','＜0.001','cox','worse\r'),(2000078,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','5.21 (1.428 to 19.034)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria','0.01','cox','worse\r'),(2000079,'27068226','TNF superfamily member 13 (TNFSF13) ','O75888','TNFSF13','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','5.31 (1.377 to 20.464)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria,smoking, hypertension, diabetes, autoimmune disease, hepatitis B antigen, anti-hepatitis C antibody, and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or steroids','0.01','cox','worse\r'),(2000080,'27055509','C3','P01024','CO3','Complement C3','protein','Renal biopsy specimens(in the mesangia area of glomeruli)','not mention','Immunofluorescence','IgAN[with microalbuminuria,followed up for >6 months](127)','the deposition of C3 in the mesangial area of glomeruli  is detectable(positive) or undetectable(negative)','positive:negative','24h urine quantitative protein being more than 1 g, or serum creatinine level becoming abnormal or double by renal biopsy','N','Kaplan-Meier ','N','univariate','N','0.019','log-rank test ','worse\r'),(2000081,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','eGFR','r','-0.646','univariate','N','＜0.001','correlation analysis','worse\r'),(2000082,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','urine protein-creatinine ratio(uPCR)','r','0.489','univariate','N','＜0.001','correlation analysis','worse\r'),(2000083,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','eGFR','r','-0.582','univariate','N','＜0.001','correlation analysis','worse\r'),(2000084,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','urine protein-creatinine ratio(uPCR)','r','0.407','univariate','N','＜0.001','correlation analysis','worse\r'),(2000085,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000086,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000087,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000088,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000089,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','0.035','log-rank test ','worse\r'),(2000090,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000091,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','7.48 (3.70–15.14)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r'),(2000092,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 2.51 (1.15–5.48)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.021','cox','worse\r'),(2000093,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','11.39 (3.26–39.85)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r'),(2000094,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 3.25 (1.00–10.54)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.05','cox','worse\r'),(2000095,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','10.32 (3.94–27.02)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r'),(2000096,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 3.96 (1.60–9.82)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.003','cox','worse\r'),(2000097,'26177311','TNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','ROC','0.808','univariate','N','not mention','ROC','worse\r'),(2000098,'26177311','TNFR2','Q12933','TRAF2','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','ROC','0.714','univariate','N','not mention','ROC','worse\r'),(2000099,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline eGFR ','N','r','-0.347','univariate','N','＜0.001','Spearman correlation analysis ','worse\r'),(2000100,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline eGFR ','N','r','-0.291','multivariate','baseline proteinuria','＜0.001','Spearman correlation analysis ','worse\r'),(2000101,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline proteinuria ','N','r','0.461','univariate','N','＜0.001','Spearman correlation analysis ','worse\r'),(2000102,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.68 (1.81–3.96)','univariate','N','＜0.001','cox','worse\r'),(2000103,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.84 (1.22–2.78)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.004','cox','worse\r'),(2000104,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.98 (1.28–3.08)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.002','cox','worse\r'),(2000105,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.74 (1.16–2.64)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.008','cox','worse\r'),(2000106,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','17.23(2.30–129.14)','univariate','N','0.006','cox','worse\r'),(2000107,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.56(1.53–84.47)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.018','cox','worse\r'),(2000108,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.49(1.52–86.93)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.018','cox','worse\r'),(2000109,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.48 (1.52–86.93)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.018','cox','worse\r'),(2000110,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','20.87(2.77–157.18)','univariate','N','0.003','cox','worse\r'),(2000111,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.56(1.64–96.25)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.015','cox','worse\r'),(2000112,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','10.71(1.29–88.63)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.014','cox','worse\r'),(2000113,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.78(1.67–97.82)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.032','cox','worse\r'),(2000114,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','9.13 (3.24–25.70) ','univariate','N','＜0.001','cox','worse\r'),(2000115,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.59(2.30–18.86) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','＜0.001','cox','worse\r'),(2000116,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.62(2.31–18.95) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','＜0.001','cox','worse\r'),(2000117,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.25 (2.18–17.90) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.001','cox','worse\r'),(2000118,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd/4th:1st/2nd','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000119,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000120,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000121,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','ROC','0.745 (0.681–0.809)','univariate','N','＜0.001','ROC','worse\r'),(2000122,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','ROC','0.724(0.630–0.817)','univariate','N','0.002','ROC','worse\r'),(2000123,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','univariate','N','0.019','cox','worse\r'),(2000124,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.019','cox','worse\r'),(2000125,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.3) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.019','cox','worse\r'),(2000126,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.019','cox','worse\r'),(2000127,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (71)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.81(1.11–2.96) ','univariate','N','0.017','cox','worse\r'),(2000128,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','univariate','N','0.014','cox','worse\r'),(2000129,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.014','cox','worse\r'),(2000130,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.014','cox','worse\r'),(2000131,'26035554','Complement factor H (CFH) ','P08603','CFAH','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.014','cox','worse\r'),(2000132,'22518072','IL-18','Q14116','IL18','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)','N','N','N','responsiveness to steroid therapy ','β','−0.003','multivariate','age, smoking and history, blood pressure, albumin, lipids, CRP, and hemoglobin at enrollment','0.01','Multivariate regression analysis ','worse\r'),(2000133,'22518072','IL-18','Q14116','IL18','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)',' IL-18 levels at baseline:346.80 pg/mL','H:L','doubling of baseline serum creatinine,ESRD (permanent hemodialysis, peritoneal dialysis, or renal transplantation) ,death from any cause. Treatment outcome','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r'),(2000134,'22518072','IL-18','Q14116','IL18','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)',' IL-18 levels at baseline:346.80 pg/mL','H:L','doubling of baseline serum creatinine,ESRD (permanent hemodialysis, peritoneal dialysis, or renal transplantation) ,death from any cause. Treatment outcome','N','β','1.98','multivariate','age, smoking and history, blood pressure, albumin, lipids, CRP, and hemoglobin at enrollment','0.001','cox','worse\r'),(2000135,'23135864','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','renal biopsies ','not mention','semi- quantitatively by counting the stained tubules per 100* power field','IgAN(69)','0 tubule( grade 0); 1–5 tubules(grade 1); 6–10 tubules(grade 2); more than 10 tubules(grade 3)','grade 3:grade 1/grade 2','a 50 % decline in eGFR or ESRD ','N','Kaplan-Meier ','N','univariate','N','0.003','log-rank test ','worse\r'),(2000136,'23135864','KIM-1 ','Q96D42','HAVR1','Hepatitis A virus cellular receptor 1','protein','renal biopsies ','not mention','semi- quantitatively by counting the stained tubules per 100* power field','IgAN(69)','0 tubule( grade 0); 1–5 tubules(grade 1); 6–10 tubules(grade 2); more than 10 tubules(grade 3)','grade 3:grade 1/grade 2','a 50 % decline in eGFR or ESRD ','N','HR','3.194(1.042–9.788)','multivariate','proteinuria, eGFR at biopsy, age, sex ','0.042','cox','worse\r'),(2000137,'25973081','mannose-binding lectin (MBL) ','P11226','MBL2','Mannose-binding protein C','protein','Renal biopsy specimens( tubulointerstitial)','not mention',' gel electrophoresis,matrix-assisted laser desorption/ionization time of  ight mass spectrometry,Immunohistochemical staining,ELISA','IgAN(131)','according to the stained degree of glomerulus.','positive:negative','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','better\r'),(2000138,'25995666','NGAL','P80188','LCN2','Neutrophil gelatinase-associated lipocalin','protein','serum ','not mention','ELISA ','IgAN(121)','N','N','N','baseline eGFR ','r','-0.225','univariate','N','0.015','Pearson or Spearman correlation coefficients','worse\r'),(2000139,'25995666','NGAL','P80188','LCN2','Neutrophil gelatinase-associated lipocalin','protein','serum ','not mention','ELISA ','IgAN(121)','N','N','N','baseline urine protein/creatinine ratio(PCR)','r','0.201','univariate','N','0.03','Pearson or Spearman correlation coefficients','worse\r'),(2000140,'25995666','NGAL','P80188','LCN2','Neutrophil gelatinase-associated lipocalin','protein','urine ','not mention','ELISA ','IgAN(121)','N','N','N','baseline eGFR ','r','-0.186','univariate','N','0.045','Pearson or Spearman correlation coefficients','worse\r'),(2000141,'25995666','NGAL','P80188','LCN2','Neutrophil gelatinase-associated lipocalin','protein','urine ','not mention','ELISA ','IgAN(121)','N','N','N','baseline serum albumin ','r','-0.315','univariate','N','0.001','Pearson or Spearman correlation coefficients','worse\r'),(2000142,'25816025','CXCL1 ','P09341','CXCL1','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r'),(2000143,'25816025','CXCL1 ','P09341','CXCL1','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','proteinuria ','r','0.155','univariate','N','0.001','Spearman’s correlation ','worse\r'),(2000144,'25816025','CXCL1 ','P09341','CXCL3','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','SBP ','r','0.138','univariate','N','0.004','Spearman’s correlation ','worse\r'),(2000145,'25816025','CXCL1 ','P09341','CXCL4','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','DBP ','r','0.114','univariate','N','0.019','Spearman’s correlation ','worse\r'),(2000146,'25816025','CXCL1 ','P09341','CXCL5','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','tubular atrophy and interstitial fibrosis ','r','0.181','univariate','N','＜0.001','Spearman’s correlation ','worse\r'),(2000147,'25816025','CXCL1 ','P09341','CXCL6','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','eGFR','r','-0.259','univariate','N','＜0.001','Spearman’s correlation ','worse\r'),(2000148,'25816025','CXCL1 ','P09341','CXCL7','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','Initial proteinuria ','β','0.128(0.585, 4.220)','multivariate','gender, age, eGFR, systolic blood pressure, diastolic blood pressure and tubular atrophy and interstitial fibrosis','0.01','linear regression analyses','worse\r'),(2000149,'25816025','CXCL1 ','P09341','CXCL8','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','HR','2.047(1.487–2.816)','univariate','N','＜0.001','cox','worse\r'),(2000150,'25816025','CXCL1 ','P09341','CXCL9','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','HR','1.748(1.222–2.499)','multivariate','gender, age, eGFR, systolic blood pressure, diastolic blood pressure and tubular atrophy and interstitial fibrosis','0.002','cox','worse\r'),(2000151,'25816025','CXCL1 ','P09341','CXCL10','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.047 (1.487–2.816)','univariate','N','＜0.001','cox','worse\r'),(2000152,'25816025','CXCL1 ','P09341','CXCL11','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.171(1.572–2.998)','multivariate','sexual,age','＜0.001','cox','worse\r'),(2000153,'25816025','CXCL1 ','P09341','CXCL12','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','1.737(1.221–2.471)','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis','0.002','cox','worse\r'),(2000154,'25816025','CXCL1 ','P09341','CXCL13','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','1.748(1.222–2.499)','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis, steroid or other immunosuppressants use (yes or no)','0.002','cox','worse\r'),(2000155,'25816025','CXCL1 ','P09341','CXCL14','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','4.624(2.309–9.260)','univariate','N','＜0.001','cox','worse\r'),(2000156,'25816025','CXCL1 ','P09341','CXCL15','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','5.023(2.492–10.124) ','multivariate','sexual,age','＜0.001','cox','worse\r'),(2000157,'25816025','CXCL1 ','P09341','CXCL16','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.879(1.407–5.892) ','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis','0.004','cox','worse\r'),(2000158,'25816025','CXCL1 ','P09341','CXCL17','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.914(1.417–5.989) ','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis, steroid or other immunosuppressants use (yes or no)','0.004','cox','worse\r'),(2000159,'23828164','URG11 ','Q96DN2','VWCE','von Willebrand factor C and EGF domain-containing protein','protein','Renal biopsy specimens(mesangial)','not mention','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','N','N','N','eGFR ','r','−0.305 ','univariate','N','0.038','linear regression analyses','worse\r'),(2000160,'23828164','URG11 ','Q96DN2','VWCE','von Willebrand factor C and EGF domain-containing protein','protein','Renal biopsy specimens(mesangial)','not mention','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','N','N','N','Tubulointerstitial fibrosis ','r','0.35','univariate','N','0.023','linear regression analyses','worse\r'),(2000161,'23828164','Twist ','Q15672','TWST1','Twist-related protein 1','protein','Renal biopsy specimens(mesangial)','tubular epithelial cells ','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','25% of the tubular epithelial cells(＞:positive；≤:negative)','Positive:negative','a 100% increase in serum creatinine from baseline or the development of end-stage renal disease (ESRD). ','N','RR','4.250 (1.170-15.446) ','multivariate','Gender ,Age (≥35),Bp,Urinary protein/24 h (≥1.0 g),eGFR (<60 mL/min),Glomerulosclerosis (≥20%),Tubulointerstitial fibrosis (≥30%),URG11 positive,URG11/Twist','0.028','cox','worse\r'),(2000162,'23611517','IL-1b','P01584','IL1B','Interleukin-1 beta','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.04fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.04','log-rank test ','worse\r'),(2000163,'23611517','IL-6','P05231','IL6','Interleukin-6','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.12fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r'),(2000164,'23611517','IL-6','P05231','IL6','Interleukin-6','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[did not responded to renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO) and steroids + azathio- pine were added] (18)','0.12fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r'),(2000165,'23611517','IL-10','P22301','IL10','Interleukin-10','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.144fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r'),(2000166,'23611517','MCP-1 ','P13500','CCL2','C-C motif chemokine 2','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','1.45fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r'),(2000167,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','H:L','ESRD ','N','Kaplan-Meier ','N','univariate','N','0.006','log-rank test ','better\r'),(2000168,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','ESRD ','N','Kaplan-Meier ','N','univariate','N','0.04','log-rank test ','worse\r'),(2000169,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','AUC','0.642','univariate','N','0.011','ROC','better\r'),(2000170,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','H:L','doubling of the baseline serum creatinine ','N','HR','0.96(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.002','cox','better\r'),(2000171,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.96(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.002','cox','better\r'),(2000172,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 3.59 (1.56–8.28)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.003','cox','better\r'),(2000173,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','14.24 (2.03–99.87)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, Tubular atrophy/interstitial fibrosis','0.008','cox','worse\r'),(2000174,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','8.76(1.39–55.2)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,serum C3 levels','0.021','cox','worse\r'),(2000175,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR',' 14.03 ( 1.86–105.77)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,serum C3 levels','0.01','cox','worse\r'),(2000176,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.95(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Mesangial C3 deposition,Tubular atrophy/interstitial fibrosis','0.004','cox','better\r'),(2000177,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 3.35 ( 1.41–7.99)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Mesangial C3 deposition,Tubular atrophy/interstitial fibrosis','0.006','cox','better\r'),(2000178,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','10.17(1.33–77.9)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Serum C3 levels,BMI, total cholesterol, serum albumin','0.026','cox','worse\r'),(2000179,'22792353','C3','P01024','CO3','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','16.18 ( 1.89–138.36)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Serum C3 levels,BMI, total cholesterol, serum albumin','0.011','cox','worse\r'),(2000180,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.96( 0.93–0.99)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Mesangial C3 deposition,BMI, total cholesterol, serum albumin','0.019','cox','better\r'),(2000181,'22792353','C3','P01024','CO3','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 2.73  (  1.09–6.86 )','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Mesangial C3 deposition,BMI, total cholesterol, serum albumin','0.032','cox','better\r'),(2000182,'24851068','β2-microglobulin (β2-MG) ','P61769','B2MG','Beta-2-microglobulin','protein','urine ','not mention','Immunofluorescence','IgAN(51)','N','N','1) a rise in SCr > 50% above baseline measurements and 2) a rise in SCr > 30% and an absolute level > 1.5 mg/dL. ','N','HR',' 1.334 ( 1.080–1.647 )','univariate','N','0.008','cox','worse\r'),(2000183,'25510296','CD147 ','P35613','BSG','Basigin','protein','Renal biopsy (in the renal tubules)','not mention','immunohistochemical staining using the avidin–biotin peroxidase complex method with an LSAB2 kit (Dako, Glostrup, Denmark) ','IgAN(?)','＜5 % staining:0; 5–25 %staining per visual field:1+;26–50 % immunostaining:2+; ＞50 % immunostaining:3+','2+/3+:0/1+','ESRD','N','Kaplan-Meier ','N','univariate','N','0','log-rank test ','worse\r'),(2000184,'25510296','CD147 ','P35613','BSG','Basigin','protein','Renal biopsy (in the renal tubules)','not mention','immunohistochemical staining using the avidin–biotin peroxidase complex method with an LSAB2 kit (Dako, Glostrup, Denmark) ','IgAN(?)','＜5 % staining:0; 5–25 %staining per visual field:1+;26–50 % immunostaining:2+; ＞50 % immunostaining:3+','2+/3+:0/1+','ESRD','N','HR','8.731 (1.095–69.596)','univariate','N','0.041','cox','worse\r'),(2000185,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial creatinine (mg/dL)','r','0.336','univariate','N','0.001','Pearson correlation coe cient ','worse\r'),(2000186,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial eGFR','r','-0.397','univariate','N','＜0.001','Pearson correlation coe cient ','worse\r'),(2000187,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial protein-creatinine ratio (PCR)','r','0.288','univariate','N','0.006','Pearson correlation coe cient ','worse\r'),(2000188,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.011 (1.004–1.017)','univariate','N','0.001','cox','worse\r'),(2000189,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.009 (1.002–1.017)','multivariate','Age','0.012','cox','worse\r'),(2000190,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.009 (1.001–1.018) ','multivariate','Age,Hypertension','0.029','cox','worse\r'),(2000191,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.012 (1.003–1.022) ','multivariate','Age,Hypertension,Proteinuria (> 1 g/day)','0.013','cox','worse\r'),(2000192,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','ROC','0.777','univariate','N','0.001','ROC','worse\r'),(2000193,'26223295','Myeloid-related proteins 8','P05109','S10A8','Protein S100-A8','protein','Renal biopsy','not mention','real-time quantitative polymerase chain reaction','LN(54)','0.5 log','H:L','2-fold increase of the serum creatinine ','N','Kaplan-Meier ','N','univariate','N','0.008','log-rank test ','worse\r'),(2000194,'26223295','Myeloid-related proteins 14','P06702','S10A9','Protein S100-A9','protein','Renal biopsy','not mention','real-time quantitative polymerase chain reaction','LN(54)','0.5 log','H:L','2-fold increase of the serum creatinine ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r'),(2000195,'25724035','COL1','P02452','COL1A1','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR   60 mL/min/1.73m2 ] (31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','6.52(1.30 to 6.61)','univariate','N','0.01','cox','worse\r'),(2000196,'25724035','COL1','P02452','COL1A1','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR   60 mL/min/1.73m2 ] (31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','4.38(1.05 to 4.55)','multivariate','Extracellular matrix index,Glomerular filtration rate,TGFB1','0.04','cox','worse\r'),(2000197,'25724035','TGFB1','P01137','TGFB1','transforming growth factor beta 1','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR   60 mL/min/1.73m2 ] (31)','7-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','5.86(1.18 to 6.36)','univariate','N','0.02','cox','worse\r'),(2000198,'25724035','COL1','P02452','COL1A1','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR   60 mL/min/1.73m2 ] (31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r'),(2000199,'25724035','TGFB1','P01137','TGFB1','transforming growth factor beta 1','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR   60 mL/min/1.73m2 ] (31)','7-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','Kaplan-Meier ','N','univariate','N','0.02','log-rank test ','worse\r'),(2000200,'24711435','\" ',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2000201,'24536044','connective tissue growth factor','P29279','CTGF','Connective tissue growth factor','protein','serum','not mention','enzyme-linked immunosorbent assay','LN(101)','normal range（didn\'t refer to Specific value）','H:L','doubling of serum creatinine','N','Kaplan-Meier ','N','univariate','N','0.0049','log-rank test ','worse\r'),(2000202,'24536044','connective tissue growth factor','P29279','CTGF','Connective tissue growth factor','protein','serum','not mention','enzyme-linked immunosorbent assay','LN(101)','N','N','doubling of serum creatinine','N','HR','1.015(1.008 to 1.022)','univariate','N','<0.001','cox','worse\r'),(2000203,'19295501','\"vascular endothelial',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2000204,'19295501','\"vascular endothelial',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2000205,'19295501','\"vascular endothelial',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(2000206,'25411257','soluble uPAR','Q03405','UPAR','Urokinase plasminogen activator surface receptor','protein','plasma','not mention','ELISA','LN(202)','N','N','The primary end point was defined as death, and secondary end points were defined as end-stage renal disease or doubling of serum creatinine.','N','HR','6.326(1.466 to 27.298)','univariate','N','0.013','cox','worse\r'),(2000207,'25411257','soluble uPAR','Q03405','UPAR','Urokinase plasminogen activator surface receptor','protein','plasma','not mention','ELISA','LN(202)','3443.4 pg/ml','H:L','The primary end point was defined as death, and secondary end points were defined as end-stage renal disease or doubling of serum creatinine.','N','Kaplan-Meier ','N','univariate','N','<0.001','log-rank test ','worse\r'),(2000208,'25196784','Human neutrophil peptide 1-3','DEFA1,DEFA3,P59665,P59666','DEF1,DEF3','Neutrophil defensin 1,Neutrophil defensin 3 ','protein','serum','not mention','ELISA','LN(40)','N','N','proteinuria remission','N','HR','0.209(0.046 to 0.951)','multivariate','age, sex, initial renal function and the use of ACEI/ARB and immunosuppressive agents ','0.043','cox','worse\r'),(2000209,'18308774','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','54 µg/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >135 µmol/l','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000210,'18308774','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','54 µg/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >135 µmol/l','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000211,'18308774','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','40 µg/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >136 µmol/l','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 82% and 90% for Uβ2m','AUC','worse\r'),(2000212,'18308774','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','40 µg/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >136 µmol/l','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 87% and 83% for Uβ2m','AUC','worse\r'),(2000213,'18308774','Uβ2m ','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','N','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >139 µmol/l','N','RR','2.69（1.82–3.98）','multivariate','serum creatinine, serum albumin, proteinuria','P < 0.001','COX','worse\r'),(2000214,'15563570','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','0.5  g/min','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r'),(2000215,'15563570','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','0.5  g/min','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 88% and 91% for Uβ2m','AUC','worse\r'),(2000216,'15563570','Uβ2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','N','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','RR','1.030(1.017-1.043)','multivariate','Serum creatinine,serum albumin,ECC,proteinuria,selectivity index,urinary excretion of albumin,beta2m, alpha1microglobulin,transferrin, IgG ','<0.001 ','COX','worse\r'),(2000217,'25098821','cTNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum','not mention','ELISA','IMN（113）',' based on cTNFRs levels tertiles','T3：T1-T2',' Renal progression was defined as a decrease in baseline eGFR by more than 30%. ','N','ROC','N','univariate','N',' 0.719 (95% confidence interval [95% CI]: 0.597–0.841), ','AUC','worse\r'),(2000218,'25098821','cTNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum','not mention','ELISA','IMN（113）',' based on cTNFRs levels tertiles','T3：T1-T2',' Renal progression was defined as a decrease in baseline eGFR by more than 31%.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000219,'25098821','cTNFR1','P19438','TNR1A','Tumor necrosis factor receptor superfamily member 1A','protein','serum','not mention','ELISA','IMN（113）','N','H:L',' Renal progression was defined as a decrease in baseline eGFR by more than 32%.','N','HR',' 3.39（1.48– 7.78）','multivariate','age, sex, presence of hypertension, eGFR, proteinuria, pathologic stage, kind of treatment, and presence of remission','0.004','Cox ','worse\r'),(2000220,'25098821','cTNFR2','P20333','TNR1B','Tumor necrosis factor receptor superfamily member 1B','protein','serum','not mention','ELISA','IMN（113）',' based on cTNFRs levels tertiles','T3：T1-T2',' Renal progression was defined as a decrease in baseline eGFR by more than 33%.','N','ROC','N','univariate','N',' 0.724 (95% CI: 0.599–0.849), ','AUC','worse\r'),(2000221,'25098821','cTNFR2','P20333','TNR1B','Tumor necrosis factor receptor superfamily member 1B','protein','serum','not mention','ELISA','IMN（113）',' based on cTNFRs levels tertiles','T3：T1-T2',' Renal progression was defined as a decrease in baseline eGFR by more than 34%.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000222,'25098821','cTNFR2','P20333','TNR1B','Tumor necrosis factor receptor superfamily member 1B','protein','serum','not mention','ELISA','IMN（113）','N','H:L',' Renal progression was defined as a decrease in baseline eGFR by more than 35%.','N','HR','3.29（1.43–7.54）','multivariate','age, sex, presence of hypertension, eGFR, proteinuria, pathologic stage, kind of treatment, presence of remission','0.005','Cox ','worse\r'),(2000223,'26296473','rbPLA2R1','P49260','PLA2R_RABIT','Secretory phospholipase A2 receptor ','protein','serum','not mention','ELISA','IMN（123）','N','N','a doubling of serum creatinine from baseline','N','multiple comparisons','','univariate','N','0.001','Kruskal-Wallis ','worse\r'),(2000224,'26296473','mPLA2R1','Q62028','PLA2R_MOUSE','Secretory phospholipase A4 receptor ','protein','serum','not mention','ELISA','IMN（41)','605 RU/mL','H:L','a doubling of serum creatinine from baseline','N','ROC','0.76（0.60，0.91）','univariate','N','100% specicity, 57% sensitivity','AUC','worse\r'),(2000225,'26296473','mPLA2R1','Q62028','PLA2R_MOUSE','Secretory phospholipase A5 receptor ','protein','serum','not mention','ELISA','IMN（42)','605 RU/mL','H:L','a doubling of serum creatinine from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000226,'25313791','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN[PLA2R抗体阳性](16)，[PLA2R抗体阴性](17)','N','H:L',' development of nephrotic range proteinuria','N','HR','3.66（1.39-9.64）','multivariate','age, sex, high proteinuria','0.009','Cox ','worse\r'),(2000227,'25313791','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN[PLA2R抗体阳性](16)，[PLA2R抗体阴性](17)','20 U/ml','positive:negative',' development of nephrotic range proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','Cox ','worse\r'),(2000228,'24610926','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(128)','N','H:L','N','N','HR','0.81(0.70-0.95)','multivariate','age, sex,proteinuria, serum creatinine, serum albumin, immunosuppressive treatment','0.008','Cox ','worse\r'),(2000229,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（81）',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete or partial remission ','N','Kaplan-Meier ','N','univariate','N','0.003','log-rank test ','worse\r'),(2000230,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（81）',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete or partial remission ','N','HR','4.198(1.919-9.185)','multivariate','sex,proteinuria, serum creatinine, anti-PLA2R antibody levels at baseline.','<0.001 ','Cox ','worse\r'),(2000231,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（81）',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','M:H','complete or partial remission ','N','HR','2.298(1.001-5.230)','multivariate','sex,proteinuria,serum creatinine,anti-PLA3R antibody levels at baseline.','0.048','Cox ','worse\r'),(2000232,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（81）',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete remission ','N','HR','3.410(1.108-10.491)','multivariate','sex,proteinuria,serum creatinine,anti-PLA4R antibody levels at baseline.','0.032','Cox ','worse\r'),(2000233,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（81）',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','M:H','complete remission ','N','HR','3.174(0.988-10.195)','multivariate','sex ,proteinuria,serum creatinine,anti-PLA5R antibody levels at baseline.','0.052','Cox ','worse\r'),(2000234,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（64）','Six-month depletion of anti-PLA2R autoantibodies','YES:NO','complete or partial remission ','N','HR','7.90(2.54-24.60)','multivariate','sex,proteinuria,serum creatinine,anti-PLA6R antibody levels at baseline.','<0.001 ','Cox ','better\r'),(2000235,'25804280','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（64）','Six-month depletion of anti-PLA5R autoantibodies','YES:NO','complete remission ','N','HR','2.89(0.63-13.36)','multivariate','sex,proteinuria,serum creatinine,anti-PLA9R antibody levels at baseline.','<0.001 ','Cox ','better\r'),(2000236,'24021909','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','western blot','IMN（91）','The presence of circulating anti-PLA2R','negative:positive','malignancies were detected','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000237,'23364522','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（82）',' tertiles','High:Mid:Low','doubling of serum creatinine','N','Kaplan-Meier ','N','multivariate','treatment','<0.001 ','Cox regression','worse\r'),(2000238,'27058841','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN-sPLA2R positive(93)','89.67U/ml','H:L','the extent of proteinuria','N','OR','4.80(1.37-16.74)','multivariate','age,hypertension,Egfr,Alb,proteinuria,gPLA2R,gender,BMI,FBG,TC,immunosuppresion,sPLA2R','0.014','Multivariate logistic regression','worse\r'),(2000239,'27058841','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN-sPLA2R positive(93)','89.67U/ml','H:L',' remission of proteinuria','N','HR','0.29(0.14-0.59)','multivariate','age,hypertension,Egfr,Alb,proteinuria,gPLA2R,gender,BMI,FBG,TC,sPLA3R','0.0007','Multivariate COX regression','worse\r'),(2000240,'27058841','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(113)','20U/ml','positive：negative',' remission of proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000241,'27058841','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN-sPLA2R positive(93)','median','H:L',' remission of proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000242,'26989120','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（514）','the presence of serum antibody','SAb+/GAg+ ：SAb-/GAg+',' complete remission ','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000243,'26989120','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（514）','the presence of serum antibody',' SAb-/GAg+：SAb+/GAg+',' complete remission ','N','HR','2.1 (1.5 to 2.9) ','multivariate','proteinuria','<0.001 ','Cox ','worse\r'),(2000244,'26989120','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','Renal biopsy','not mention','Immunohistological staining','IMN（20）','the presence of antigen','GAg+ ：GAg-','relapse ','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r'),(2000245,'26989120','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','Renal biopsy','not mention','Immunohistological staining','IMN（21）','intensity of GAg staining ','','relapse ','N','HR','3.1 (1.3 to 7.2) ','multivariate','complete remission/partial remission status','<0.01 ',' Cox ','worse\r'),(2000246,'25953939','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','immunofluorescence assay','IMN（37）','0.048611111','H:L','achieving treatment-induced complete or partial remission ','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r'),(2000247,'26344651','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（73）','N','L:H','induced remission,relapse of proteinuria,ESRD,mortality;appearance  of  a  spontaneous remission, defined as induction of either a complete or partial remission (PR) without the use of immunosuppressive agents','N','HR','2.72 (1.22–6.08)','multivariate','age, male gender, rate of proteinuria, serum creatinine','0.02',' Cox ','better\r'),(2000248,'26344651','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（73）','N','L:H','induced remission,relapse of proteinuria,ESRD,mortality;appearance  of  a  spontaneous remission, defined as induction of either a complete or partial remission (PR) without the use of immunosuppressive agents','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','better\r'),(2000249,'25035272','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN（33）','40 U/ml','negative：positive',' relapse, death, or start of additional immunosuppressive therapy)','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000250,'18403431','L-FABP','P07148','FABPL','Fatty acid-binding protein, liver','protein','urine','not mention','ELISA','IMN（40）','5.7 µg/mmol Cr ','H:L','Renal failure was defined as an increase in serum creatinine >25% from baseline with a serum creatinine >135 µmol/l or an increase >50% from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000251,'18403431','H-FABP','P05413','FABPH','Fatty acid-binding protein, heart','protein','urine','not mention','ELISA','IMN（40）','3.1 µg/mmol Cr','H:L','Renal failure was defined as an increase in serum creatinine >25% from baseline with a serum creatinine >135 µmol/l or an increase >50% from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000252,'22801951','β2-microglobulin','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（57）','0.5  g per min','H:L','Renal death was defined as an increase in serum creatinine to >133 µmol/l or an increase >50% ','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r'),(2000253,'22801951','β2-microglobulin','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN（104）','N','N','The end point of the study was progression of the disease, defined as an increase in serum creatinine concentration of >50%, or of >25% with an absolute concentration of >135 mmol/l.','N','ROC','0.80 (0.71–0.89)','univariate','N','N','AUC','worse\r'),(2000254,'22801951','α1-microglobulin','P02760','AMBP','Protein AMBP','protein','urine','not mention','ELISA','IMN（104）','N','N','The end point of the study was progression of the disease, defined as an increase in serum creatinine concentration of >50%, or of >25% with an absolute concentration of >135 mmol/l.','N','ROC','0.79 (CI 0.71–0.88),','univariate','N','N','AUC','worse\r'),(2000255,'15361701','CD68','P34810','CD68','Macrosialin (Gp110) (CD antigen CD68)','protein','renal tissue','not mention','immunohistochemical assays','IMN(30)','N','Yes:No','ESRF','N','HR','1.039','multivariate','FSGS,MCP-1,CD68-postive cell','0.0061','multivariate stepwise Cox hazard analysis','worse\r'),(2000256,'18753796','NGAL','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','urine','not mention','ELISA','MN(23)','350 ng/ml','H:L','chronic  worsening  in  renal  function  (decrease  in  GFR≥5 0%  of  baseline  values).','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 90.9% and 91.7% ','AUC','worse\r'),(2000257,'18753796','NGAL','P80188','NGAL','Neutrophil gelatinase-associated lipocalin','protein','urine','not mention','ELISA','MN(23)','350 ng/ml','H:L','appearance of a chronic severe decrease in GFR≥ 50% of baseline values','N','HR','3.36（1.26-8.95）','univariate','N','0.003','Cox ','worse\r'),(2000258,'22595828','β2m','P61769','B2MG','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(104）','0.8ug/min','H:L','N','N','ROC','0.80（0.71–0.89）','univariate','N','0.84','AUC','worse\r'),(2000259,'22595828','α1m','P02760','AMBP','Protein AMBP','protein','urine','not mention','BNII nephelometer','IMN(104）','0.79ug/min','H:L','N','N','ROC','0.79（0.71–0.88）','univariate','N','0.85','AUC','worse\r'),(2000260,'25267554','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(118）','N','H:L','an increase of serum creatinine by ≥25% and serum creatinine reaching ≥1.3 mg/dl.','N','HR','1.6（1.02-2.5）','multivariate','age, sex,total IgG PLA2R-Ab levels, IgG4 PLA2R-Ab levels, proteinuria,serum albumin, serum creatinine, time between renal biopsy and measurement of PLA2R-Ab levels, glomerular lesions according to the work by Ehrenreich and Churg, BP,use of immunosuppressive treatment','0.04','COX','worse\r'),(2000261,'25267554','PLA2R','Q13018','PLA2R','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(118）','tertile 1 levels=20–86 units/ml (low), tertile 2 levels=87–201 units/ml(medium), and tertile 3 levels $202 units/ml (high).','H:L','an increase of serum creatinine by ≥25% and serum creatinine reaching ≥1.3 mg/dl.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r'),(2000262,'25129203','nestin','P48681','NEST','Nestin','Protein','renal tissue','not mention','PAS','FSGS(38)','25%(the estimated percentage of glomerular nestin expression in the whole biopsy sample)','H:L','CKD2–5','N','Kaplan-Meier method，logistic regression','3.964','univariate','N','0.046','log-rank test ','better\r'),(2000263,'16967287','HLA-DR3','Q29905','Q29905','HLA-DR3 protein','DNA','blood','not mention','polymerase chain reaction sequence-specific oligonucleotide probing technique and the microlymphocytotoxicity test. ','FSGS(48)','yes or no ','positive:negative','remission (a reduction in rate of urinary protein excretion to less than 4 mg/h/m2 for three consecutive days)','N','Kaplan-Meier method，logistic regression','N','univariate','N','0.01','log-rank test ','better\r');

--
-- Table structure for table `snp`
--

CREATE TABLE `snp` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `originalname` varchar(1000) DEFAULT NULL,
  `snpfunction` varchar(100) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `descript` varchar(1000) DEFAULT NULL,
  `genetyep` varchar(500) DEFAULT NULL,
  `dbsnp` varchar(100) DEFAULT NULL,
  `snptype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `snp`
--

INSERT INTO `snp` VALUES (0,'11967037','uteroglobin','uteroglobin G38A polymorphism',' ','SCGB1A1','secretoglobin family 1A member 1','GG',' ','SNP','peripheral blood cells ','not mention','PCR-RFLP ','IgAN[with hypertension at the time of renal biopsy](97)','genotype  with or without the A allele','GG：AG/AA','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','multivariate','hypertension','0.038','log-rank test ','worse\r'),(30000002,'11967037','uteroglobin','uteroglobin G38A polymorphism',' ','SCGB1A1','secretoglobin family 1A member 1','GG',' ','SNP','peripheral blood cells ','not mention','PCR-RFLP ','IgAN[with a proteinuria level of more than 2 g/day at the time of renal biopsy](78)','genotype  with or without the A allele','GG：AG/AA','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','multivariate','proteinuria level ','0.014','log-rank test ','worse\r'),(30000003,'12005241','IgH','VNTR allele of the hs1,2 enhancer of the α1 gene of the IgH locus ','hs1,2 enhancer of the α1 gene of the IgH locus ','IGH','immunoglobulin heavy locus','Allele B positive',' ','VNTR','blood','not mention','PCR-SSP','IgAN(125)','genotype Allele B negative or positive','positive：negative','aggravation（initiation of chronic renal failure or transplantation）','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','worse\r'),(30000004,'12172761','ACE','Angiotensin-converting enzyme (ACE) I/D polymorphism ',' ','ACE','angiotensin I converting enzyme','D','rs1799752','insert/deletion','blood','not mention','PCR','IgAN(79)','genotype ','D：II','ESRD ','N','HR','2.37（1.08–5.21）','multivariate','Grade of proteinuria ','0.031','cox','worse\r'),(30000005,'12172761','ACE','Angiotensin-converting enzyme (ACE) I/D polymorphism ',' ','ACE','angiotensin I converting enzyme','DD','','insert/deletion','blood','not mention','PCR','IgAN(79)','','DD:ID/II','','N','RR','4.74','','','','','worse\r'),(30000006,'12164881','Angiotensinogen(AGT)','A(-20)C polymorphism of the Angiotensinogen gene',' ','AGT','angiotensinogen','C(-20)]','','SNP','blood','not mention','PCR','IgAN(137)','genotype  with or without the C allele','AC/CC:AA','doubling of Scr or initiation of hemodialysis','N','Kaplan-Meier ','N','univariate ','N','0.008','log-rank test ','worse\r'),(30000007,'12164881','Angiotensinogen(AGT)','the M235T polymorphism of the Angiotensinogen gene',' ','AGT','angiotensinogen','TT','','SNP','blood','not mention','PCR','IgAN(137)','genotype  with or without the M allele','TT:MM/MT','doubling of Scr or initiation of hemodialysis','N','Kaplan-Meier ','N','univariate ','N','0.02','log-rank test ','worse\r'),(30000008,'12164881','Angiotensinogen(AGT)','A(-20)C polymorphism of the Angiotensinogen gene',' ','AGT','angiotensinogen','C(-20)]','','SNP','blood','not mention','PCR','IgAN(137)','genotype  with or without the C allele','AC/CC:AA','doubling of Scr or initiation of hemodialysis','N','HR','3.6(1.5-8.7)','multivariate','urinary protein,hypertention at renal biopsy','0.004','cox','worse\r'),(30000009,'12484505','SA','SA genotype (Genetic Polymorphism in the SA Gene )',' ','ACSM3','acyl-CoA synthetase medium-chain family member 3 ','A1','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(274)','genotype  with or without the A2 allele','A1A1:A1A2/A2A2','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','univariate ','N','0.0748','log-rank test ','worse\r'),(30000010,'12566518','CD14 ','CD14 gene –159C polymorphism ',' ','CD14','CD14 molecule','CC','','SNP','blood','not mention','PCR-RFLP ','IgAN(216)','genotype ','CC:TC/TT','doubling the baseline serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.03','log-rank test ','worse\r'),(30000011,'12566518','CD14 ','CD14 gene –159C polymorphism ',' ','CD14','CD14 molecule','CC','','SNP','blood','not mention','PCR-RFLP ','IgAN[with CD14 genetype of CC or TT](106)','genotype ','CC:TT','doubling the baseline serum creatinine ','N','HR','3.2(1.2-8.8)','univariate ','N','0.025','cox','worse\r'),(30000012,'12746403','aldosterone synthase (CYP11B2)','CYP11B2 C-344T polymorphism ',' ','CYP11B2','cytochrome P450 family 11 subfamily B member 2','CC','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(271)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.0225','log-rank test ','worse\r'),(30000013,'12746403','aldosterone synthase (CYP11B2)','CYP11B2 C-344T polymorphism ',' ','CYP11B2','cytochrome P450 family 11 subfamily B member 2','CC','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(271)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','2.099(1.098-4.013)','univariate ','N','0.0249','cox','worse\r'),(30000014,'12746403','aldosterone synthase (CYP11B2)','CYP11B2 C-344T polymorphism ',' ','CYP11B2','cytochrome P450 family 11 subfamily B member 2','CC','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN[female](143)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','4.284(1.686-10.881)','multivariate','Hypertension,No ACEI/ARB administration,urinary protein','0.0022','cox','worse\r'),(30000015,'12746403','aldosterone synthase (CYP11B2)','CYP11B2 C-344T polymorphism ',' ','CYP11B2','cytochrome P450 family 11 subfamily B member 2','CC','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN[female](143)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.0002','log-rank test ','worse\r'),(30000016,'12885793','ADD1 ','ADD1 G460W polymorphisms ',' ','ADD1','adducin 1','WW','','SNP','peripheral blood cell','not mention','allele-specific oligonucleotide hybridization after PCR amplification. ','IgAN[carrying the ACE II genotype](106)','genotype ','WW:GW/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','Kaplan-Meier ','N','univariate ','N','0.0138','log-rank test ','worse\r'),(30000017,'12885793','ADD1 ','ADD1 G460W polymorphisms ',' ','ADD1','adducin 1','WW','','SNP','peripheral blood cell','not mention','allele-specific oligonucleotide hybridization after PCR amplification. ','IgAN[carrying the ACE II genotype](106)','genotype ','WW:GW/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.65(1.63-8.20)','multivariate','hypertension,No ACEI/ARB administration,urinary protein excretion','0.0016','cox','worse\r'),(30000018,'14616762','Peroxisome proliferator-activated receptor γ (PPARγ) ','PPARG C161T polymorphism',' ','PPARG','peroxisome proliferator activated receptor gamma','T','','SNP','peripheral blood cell','not mention','PCR-RFLP ','IgAN[without hypertension](106)','genotype ','CT/TT:CC','ESRD(when patients underwent first hemodialysis)','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','better\r'),(30000019,'14684698','ACE ','ACE A2350Gpolymorphism ',' ','ACE','angiotensin I converting enzyme','AA','','SNP','peripheral blood cells ','not mention','PCR','IgAN[who did receive treatment with ACE inhibitor or ARB](114)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','Kaplan-Meier ','N','univariate ','N','0.0332','log-rank test ','worse\r'),(30000020,'14684698','ACE ','ACE A2350Gpolymorphism ',' ','ACE','angiotensin I converting enzyme','AA','','SNP','peripheral blood cells ','not mention','PCR','IgAN(267)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.599(1.033-2.475)','univariate ','N','0.0352','cox','worse\r'),(30000021,'14684698','ACE ','ACE A2350Gpolymorphism ',' ','ACE','angiotensin I converting enzyme','AA','','SNP','peripheral blood cells ','not mention','PCR','IgAN(267)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.794(1.112-2.894)','multivariate','\"Urinary protein excretion,Hypertension,No administration',NULL,NULL,NULL),(30000022,'14990020','uteroglobin ','UteroglobinG38A polymorphism',' ','SCGB1A1','secretoglobin family 1A member 1','AA','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(300)','genotype ','AA:AG/GG','PRD','N','OR','2.37(1.12-5.01)','univariate ','N','＜0.01','chi-square test ','worse\r'),(30000023,'15031629','angiotensinogen','angiotensinogen gene M235T polymorphism ',' ','AGT','angiotensinogen','MM','','SNP','blood','not mention','PCR','IgAN(107)','genotype ','MM:MT/TT','end-stage renal disease or doubling of the initial serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','＜0.05','log-rank test ','better\r'),(30000024,'15730046','TGF-β1','TGF-β1 C-509T polymorphism','at the promoter region ','TGFB1','TGFB1','TT','','SNP','blood','not mention','PCR-RFLP ','IgAN(108)','genotype ','TT:CC/CT','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.042','log-rank test ','worse\r'),(30000025,'16029633','MUC20','MUC20 VNTR polymorphism',' ','MUC20','mucin 20, cell surface associated','SL/LL','','VNTR ','blood','not mention','PCR','IgAN[followed up for 1-7 years](113)','genotype ','SL/LL:SS','ESRD','N','OR','7.29(1.68-31.60)','univariate ','N','0.008','cox','worse\r'),(30000026,'16362156','Monocyte chemoattractant protein (MCP)-1 ','MCP-1 A-2518G gene polymorphism',' ','CCL2','C-C motif chemokine ligand 2','AA','','SNP','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG:GG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.0029','log-rank test ','worse\r'),(30000027,'16362156','Monocyte chemoattractant protein (MCP)-1 ','MCP-1 A-2518G gene polymorphism',' ','CCL2','C-C motif chemokine ligand 2','AA','','SNP','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.0006','log-rank test ','worse\r'),(30000028,'16362156','Monocyte chemoattractant protein (MCP)-1 ','MCP-1 A-2518G gene polymorphism',' ','CCL2','C-C motif chemokine ligand 2','AA','','SNP','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG:GG','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.01','log-rank test ','worse\r'),(30000029,'16362156','Monocyte chemoattractant protein (MCP)-1 ','MCP-1 A-2518G gene polymorphism',' ','CCL2','C-C motif chemokine ligand 2','AA','','SNP','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.0024','log-rank test ','worse\r'),(30000030,'16362156','Monocyte chemoattractant protein (MCP)-1 ','MCP-1 A-2518G gene polymorphism',' ','CCL2','C-C motif chemokine ligand 2','AA','','SNP','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','ESRD','N','HR','2.058(1.092-3.876)','multivariate','Sex,Age at onset,Urinary protein excretion at biopsy,Glomerular filtration rate < 60ml/min,Presence of hypertension,Absence of ACEI/ARB administration','0.026','cox','worse\r'),(30000031,'16395252','The chemokine (CK) receptor 5 (CCR5) ','d32–CCR5 polymorphism ',' ','CCR5','C-C motif chemokine receptor 5','d32 ','','SNP','peripheral blood ','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','d32d32 /d32nl :nlnl ','renal/patient death event or censore （primary endpoint）','N','Kaplan-Meier ','N','univariate ','N','0.002','log-rank test ','worse\r'),(30000032,'16395252','The chemokine (CK) receptor 5 (CCR5) ','d32–CCR5 polymorphism ',' ','CCR5','C-C motif chemokine receptor 5','d32 ','','SNP','peripheral blood ','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','d32d32 /d32nl :nlnl ','CRF (＜60 ml/ min)event or censored（secondary endpoint）','N','Kaplan-Meier ','N','univariate ','N','0.03','log-rank test ','worse\r'),(30000033,'16395252','The chemokine (CK) receptor 5 (CCR5) ','d32–CCR5 polymorphism ',' ','CCR5','C-C motif chemokine receptor 5','nl','','SNP','peripheral blood ','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','nlnl:d32d32 /d32nl ','ESRF ','N','HR','0.31 (0.15–0.65)','multivariate','Proteinuria/RB1,GOS1,CRF/RB1,Hypertension/RB1,Age at onset,Overweight/obesity:,Gender','0.002','cox','better\r'),(30000034,'16395252','The chemokine (CK) receptor 5 (CCR5) ','d32–CCR5 polymorphism ',' ','CCR5','C-C motif chemokine receptor 5','nl','','SNP','peripheral blood ','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','nlnl:d32d32 /d32nl ','CRF (o60 ml/min) ','N','HR','0.57 (0.35–0.95)','multivariate','Proteinuria/RB1,GOS1,CRF/RB1,Hypertension/RB1,Age at onset,Overweight/obesity:,Gender','0.03','cox','better\r'),(30000035,'16508246','MUC20 ','MUC20 VNTR polymorphism',' ','MUC20','mucin 20, cell surface associated','SL/LL','','VNTR ','peripheral white blood cells of the whole blood samples ','not mention','PCR,1.5% agarose gel electrophoresis,sequencing','IgAN[followed up for 60.6±22.4 years](113)','genotype ','SL/LL:SS','ESRD or doubling of the initial serum creatinine ','N','Kaplan-Meier ','N','univariate ','N',' ＜0.001','log-rank test ','worse\r'),(30000036,'16508246','MUC20 ','MUC20 VNTR polymorphism',' ','MUC20','mucin 20, cell surface associated','SL/LL','','VNTR ','peripheral white blood cells of the whole blood samples ','not mention','PCR,1.5% agarose gel electrophoresis,sequencing','IgAN[followed up for 60.6±22.4 years](113)','genotype ','SL/LL:SS','ESRD or doubling of the initial serum creatinine ','N','OR','20.9(2.6–168.1)','multivariate','hypertension,chronic kidney disease stage,glomerular pathological scores ','0.004','cox','worse\r'),(30000037,'16526314','Vascular endothelial growth factor (VEGF) ','VEGF-2578 genotype. ',' ','VEGFA','vascular endothelial growth factor A','CC','','SNP','peripheral blood leukocytes ','not mention','PCR, electrophoresed through a 2% agarose gel.','IgAN(195)','genotype ','CC:CA/AA','kidney survival as measured by the time interval from renal biopsy to end-stage renal disease or the requirement of renal replacement therapy.','N','Kaplan-Meier ','N','univariate ','N','0.023','log-rank test ','worse\r'),(30000038,'17338426',' Clara cell secretory protein (CC16)','CC16 G38A polymorphism',' ','SCGB1A1','secretoglobin family 1A member 1 ','AA','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(267)','genotype ','AA:AG:GG','doubling of serum creatinine (Scr) level or progression to end- stage renal disease requiring renal replace- ment therapy ','N','Kaplan-Meier ','N','univariate ','N','0.043','log-rank test ','worse\r'),(30000039,'17338426',' Clara cell secretory protein (CC16)','CC16 G38A polymorphism',' ','SCGB1A1','secretoglobin family 1A member 1 ','AA','','SNP','peripheral blood ','not mention','PCR-RFLP ','IgAN(267)','genotype ','AA:AG/GG','doubling of serum creatinine (Scr) level or progression to end- stage renal disease requiring renal replace- ment therapy ','N','HR','2.344(1.185–4.638)','multivariate','Presence of hypertension,Initial creatinine (per 1 mg/dl),Proteinuria* (3 3.0 g/day)','0.014','cox','worse\r'),(30000040,'18793525','Megsin','Megsin C2093T polymorphism',' ','SERPINB7','serpin family B member 7','CC','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CC:CT/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.027','log-rank test ','better\r'),(30000041,'18793525','Megsin','Megsin C2180T polymorphism',' ','SERPINB7','serpin family B member 7','TT','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','TT:CC/CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.025','log-rank test ','better\r'),(30000042,'18793525','Megsin','Megsin C2093T-C2180T haplotype','3\'UTR','SERPINB7','serpin family B member 7','TC','','haplotype','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing,PHASE PROGRAME','IgAN(260)','genotype ','TC:CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.028','log-rank test ','worse\r'),(30000043,'18793525','Megsin','Megsin C2093T polymorphism',' ','SERPINB7','serpin family B member 7','TT','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','TT:CC/CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','3.52(1.69–7.34)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.001','cox','worse\r'),(30000044,'18793525','Megsin','Megsin C2093T polymorphism',' ','SERPINB7','serpin family B member 7','CT','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CT:CC/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.15(1.30–3.57)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.003','cox','worse\r'),(30000045,'18793525','Megsin','Megsin C2180T polymorphism',' ','SERPINB7','serpin family B member 7','CC','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CC:CT/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','4.05(1.93–8.51)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0','cox','worse\r'),(30000046,'18793525','Megsin','Megsin C2180T polymorphism',' ','SERPINB7','serpin family B member 7','CT','','SNP','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CT:CC/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.35(1.40–3.97)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.001','cox','worse\r'),(30000047,'18793525','Megsin','Megsin C2093T-C2180T haplotype','3\'UTR','SERPINB7','serpin family B member 7','TC','','haplotype','peripheral blood ','not mention','Taqman assay,PCR,DNA sequencing,PHASE PROGRAME','IgAN(260)','genotype ','TC:CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.010(1.438–2.808)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0','cox','worse\r'),(30000048,'19194560','Angiotensin II type 2 receptor (AT2R) ','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism','intron 2 ','AGTR2','angiotensin II receptor type 2','T','','SNP','peripheral blood ','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Kaplan-Meier ','N','univariate ','N','0.0236','log-rank test ','better\r'),(30000049,'19194560','Angiotensin II type 2 receptor (AT2R) ','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism','intron 2 ','AGTR2','angiotensin II receptor type 2','T','','SNP','peripheral blood ','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Exp (B) ','0.309(0.111–0.862)','univariate ','N','0.025','cox','better\r'),(30000050,'19194560','Angiotensin II type 2 receptor (AT2R) ','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism','intron 2 ','AGTR2','angiotensin II receptor type 2','T','','SNP','peripheral blood ','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Exp (B) ','0.221(0.052–0.940)','multivariate','age, sex, serum creatinine level, the degree of proteinuria ','0.041','cox','better\r'),(30000051,'27450519','not mention','rs 2856717 ','','','','CC','rs 2856717 ','SNP','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[followed up for 44.49±19.94 years](315)','genotype ','CC:TT/TC','a doubling of serum creatinine levels compared to the levels measured at renal biopsy, a need for renal replacement therapy or death','N','Kaplan-Meier ','N','univariate ','N','0.046','log-rank test ','better\r'),(30000052,'27450519','not mention','rs 2856717 ','','','','TT/TC','rs 2856717 ','SNP','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[followed up for 44.49±19.94 years](315)','genotype ','TT/TC:CC','eGFR decline≥50% ','N','RR','1.8(1.78–3.46)','multivariate','age,hypertension,GFR ≤ 60 mL/min','0.01','cox','worse\r'),(30000053,'19729965','angiotensinogen (AGT)','AGT M235T','','AGT','angiotensinogen','TT','','SNP','peripheral blood ','not mention','TaqMan PCR, DNA sequencing','IgAN[male](130)','genotype ','TT:MM/MT',' doubling of Cr or progression to ESRD ','N','Kaplan-Meier ','N','univariate ','N','0.01','log-rank test ','worse\r'),(30000054,'19729965','angiotensinogen (AGT)','AGT M235T','','AGT','angiotensinogen','TT','','SNP','peripheral blood ','not mention','TaqMan PCR, DNA sequencing','IgAN[male](130)','genotype ','TT:MM/MT',' doubling of Cr or progression to ESRD ','N','HR','5.704(1.578–20.618)','multivariate','age at diagnosis, hypertension, serum creatinine and urinary protein excretion at renal biopsy','0.008','cox','worse\r'),(30000055,'19967654','TGF-β1','TGF-β1 T869C (COD 10) ','','TGFB1','TGFB1','CC','','SNP','peripheral blood leukocytes ','not mention','PCR, electrophoresed through an agarose gel.','IgAN(105)','genotype ','CC:TT/TC','ESRD or creatinine doubling','N','Kaplan-Meier ','7.81','univariate ','N','0.009','log-rank test ','better\r'),(30000056,'19967654','TGF-β1','TGF-β1 T869C (COD 10) ','','TGFB1','TGFB1','CT/TT','','SNP','peripheral blood leukocytes ','not mention','PCR, electrophoresed through an agarose gel.','IgAN(105)','genotype ','TT/TC:CC','ESRD or creatinine doubling','N','OR','19.5(1.6-131.9)','multivariate','Sex (male),Age,SCr (≥1.4 in males, ≥1.2 in females),UProt (<1 g/24 hours),Hypertension,ACE-Is /ARBs','0.018','cox','worse\r'),(30000057,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ',' ','EPHX2','epoxide hydrolase 2','AA/AG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','AA/AG:GG','ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','＜0.001','log-rank test ','better\r'),(30000058,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','AA/AG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[eGFR＞60](257)','genotype ','AA/AG:GG','ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','better\r'),(30000059,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','GG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.10(1.35–3.25)','univariate ','N','0.001','cox','worse\r'),(30000060,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','GG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.07(1.33–3.21)','multivariate','age,gender','0.001','cox','worse\r'),(30000061,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','GG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.02(1.29–3.17)','multivariate','age, gender, hypertension, diabetes mellitus','0.002','cox','worse\r'),(30000062,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','GG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','1.83(1.13–2.96)','multivariate','age, gender, hypertension, diabetes mellitus, initial proteinuria','0.014','cox','worse\r'),(30000063,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ','','EPHX2','epoxide hydrolase 2','GG','rs751141','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[eGFR＞60](257)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.45(1.14–5.24)','multivariate','age, gender, Initial eGFR,Initial proteinuria,hypertension,diabetes mellitus','0.021','cox','better\r'),(30000064,'23147162','Klotho ','Klotho G395A','','KL','klotho','GG','','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(973)','genotype ','GG:AA/AG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','better\r'),(30000065,'25973081','mannose-binding lectin (MBL) ','SNP in condon 54 of exon region of MBL gene','in condon 54 of exon region','MBL2','mannose binding lectin 2','mutant','','SNP','peripheral venous blood ','not mention','semi-nest- ed ampli cation,capillary electrophoresis sequencing,','IgAN(131)','genotype ','mutant:wild','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.005','log-rank test ','worse\r'),(30000066,'25973081','mannose-binding lectin (MBL) ','SNP in condon 54 of exon region of MBL gene','in condon 54 of exon region','MBL2','mannose binding lectin 2','mutant','','SNP','peripheral venous blood ','not mention','semi-nest- ed ampli cation,capillary electrophoresis sequencing,','IgAN(131)','genotype ','mutant:wild','ESRD','N','β','2.46','multivariate','initial Scr,DBP,TID','0.033','log-rank test ','worse\r'),(30000067,'15610230','Chemokine receptor 5 (CCR5) ','CCR5 delta 32','','CCR5','C-C motif chemokine receptor 5 (gene/pseudogene)','mutant','','genotype','peripheral blood leukocytes ','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','Kaplan-Meier ','N','univariate ','N','< 0.001 ','log-rank test ','better\r'),(30000068,'15610230','Chemokine receptor 5 (CCR5) ','CCR5 delta 32','','CCR5','C-C motif chemokine receptor 5 (gene/pseudogene)','mutant','','genotype','peripheral blood leukocytes ','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','HR','0.29 (0.13–0.62) ','univariate ','N','0.001','cox','better\r'),(30000069,'15610230','Chemokine receptor 5 (CCR5) ','CCR5 delta 32','','CCR5','C-C motif chemokine receptor 5 (gene/pseudogene)','mutant','','genotype','peripheral blood leukocytes ','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','HR','0.23 (0.09–0.57) ','multivariate','Serum creatinine,Proteinuria >1 g/24 hours,Hypertension,Gender,Age','0.002','cox','better\r'),(30000070,'19420105','GPIa ','GPIa C807T ','','ITGA2','integrin subunit alpha 2','TT','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC/CT','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0005','log-rank test ','worse\r'),(30000071,'19420105','GPIa ','GPIa C807T ','','ITGA2','integrin subunit alpha 2','TT','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC/CT','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','multivariate','adjusted for multiple comparisons by the method of Bonferroni. ','0.0174','log-rank test ','worse\r'),(30000072,'19420105','ICAM-1 ','ICAM-1 A1548G (K469E) ','','ICAM1','intercellular adhesion molecule 1','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0013','log-rank test ','worse\r'),(30000073,'19420105','ICAM-1 ','ICAM-1 A1548G (K469E) ','','ICAM1','intercellular adhesion molecule 1','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','multivariate','adjusted for multiple comparisons by the method of Bonferroni. ','0.043','log-rank test ','worse\r'),(30000074,'19420105','ACE ','ACE I/D ','','ACE','angiotensin I converting enzyme','DD ','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','DD:ID/II','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0177','log-rank test ','worse\r'),(30000075,'19420105','PGC-1α','PGC-1 G1564A (G482S) ','','PPARGC1A','PPARG coactivator 1 alpha','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0193','log-rank test ','worse\r'),(30000076,'19420105','GPIa ','GPIa C807T ','','ITGA2','integrin subunit alpha 2','TT','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.29 (1.32–3.99) ','univariate ','N','0.003','cox','worse\r'),(30000077,'19420105','GPIa ','GPIa C807T ','','ITGA2','integrin subunit alpha 2','TT','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.05 (1.13–3.71) ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) ,genotypes of ICAM-1 A1548G (1548AA, AG and GG).','0.018','cox','worse\r'),(30000078,'19420105','ICAM-1 ','ICAM-1 A1548G ','','ICAM1','intercellular adhesion molecule 1','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.25 (1.29–3.92) ','univariate ','N','0.004','cox','worse\r'),(30000079,'19420105','ICAM-1 ','ICAM-1 A1548G ','','ICAM1','intercellular adhesion molecule 1','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.55 (1.40–4.65) ','univariate ','baseline clinical characteristics (facility, age, gender, body mass index, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) ,genotypes of GPIa C807T (807CC, CT and CT) ','0.002','cox','worse\r'),(30000080,'19420105','GPIa ','GPIa C807T ','','ITGA2','integrin subunit alpha 2','TT','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','N','slope of eGFR ','β-coeff icient ','−1.98 ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, systolic blood pressure, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) and genotypes of ICAM-1 A1548G (1548AA, AG and GG).','0.031','linear regression model ','worse\r'),(30000081,'19420105','ICAM-1 ','ICAM-1 A1548G ','','ICAM1','intercellular adhesion molecule 1','GG','','SNP','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','N','slope of eGFR ','β-coeff icient ','−2.21 ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, systolic blood pressure, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) and genotypes of GPIa C807T (807CC, CT and CT) ','0.016','linear regression model ','worse\r'),(30000082,'21150220','CMA ','rs1800875 ','','CMA1','chymase 1','AA/AG ','rs1800875 ','SNP','peripheral blood ','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','AA/AG:GG','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','worse\r'),(30000083,'21150220','CMA ','rs1800876 ','','CMA1','chymase 1','CC/CT','rs1800876 ','SNP','peripheral blood ','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','CC/CT:TT','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','Kaplan-Meier ','N','univariate ','N','0.035','log-rank test ','worse\r'),(30000084,'21150220','CMA ','rs1800875 ','','CMA1','chymase 1','AA/AG ','rs1800875 ','SNP','peripheral blood ','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','AA/AG:GG','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','HR','2.351 (1.414–3.908) ','multivariate','hypertension, higher glomerular grades, advanced tubulointerstitial lesions, a urinary pro- tein excretion of more than 1.5 g/day, an elevated baseline,serum Cr level','0.001','cox','worse\r'),(30000085,'21245129','MYH9 ','rs11089788 ','','MYH9','myosin heavy chain 9','AA/AC','rs11089788 ','SNP','blood ','not mention','TaqMan assay or a restriction fragment length polymorphism assay ','IgAN[regularly followed and the mean follow-up duration was 31.3±17.7 months](384)','genotype ','AA/AC:CC','ESRD','N','HR','3.95(1.23–12.63)','multivariate','time-average proteinuria,serum creatinine,Haas','0.021','cox','worse\r'),(30000086,'24452035','ACE ','ACE insertion/deletion polymorphism (rs1799752) ',' ','ACE','angiotensin I converting enzyme','DD ','rs1799752','SNP','blood','not mention','PCR','IgAN(237)','genotype ','DD:ID/II','50% increase in serum creatinine level ','N','HR','1.97 (1.15-3.40) ','multivariate','facility ','0.014','cox','worse\r'),(30000087,'24452035','ACE ','ACE insertion/deletion polymorphism (rs1799752) ',' ','ACE','angiotensin I converting enzyme','DD ','rs1799752','SNP','blood','not mention','PCR','IgAN(237)','genotype ','DD:ID/II','50% increase in serum creatinine level ','N','HR','1.86 (1.03, 3.33) ','multivariate','facility, clinical characteristics at kidney biopsy (age, gender, smoking status, hyperten- sion, eGFR, urinary protein, and urinary occult blood); ACE I/D and therapeutic interventions within one year of kidney biopsy (RAS blockade and use of immunosuppressants) ','0.038','cox','worse\r'),(30000088,'27358498','DEFA1A3','DEFA1A3 CNV','','DEFA1A3','defensin alpha 1 and alpha 3, variable copy number locus',' ','','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q2:Q3:Q4:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','Kaplan-Meier ','N','univariate ','N','0.0008','log-rank test ','better\r'),(30000089,'27358498','DEFA1A3','DEFA1A3 CNV','','DEFA1A3','defensin alpha 1 and alpha 3, variable copy number locus',' ','','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)','N','N ','ESRD or doubling of serum creat- inine after diagnosis','N','HR','0.78 (0.66–0.92)','univariate ','N','0.004','cox','better\r'),(30000090,'27358498','DEFA1A3','DEFA1A3 CNV','','DEFA1A3','defensin alpha 1 and alpha 3, variable copy number locus',' ','','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)','N','N ','ESRD or doubling of serum creat- inine after diagnosis','N','HR','0.79 (0.66–0.95)','multivariate','age, gender, proteinuria, hypertension, and serum creatinine at biopsy','0.012','cox','better\r'),(30000091,'27358498','DEFA1A3','DEFA1A3 CNV','','DEFA1A3','defensin alpha 1 and alpha 3, variable copy number locus',' ','','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','HR','5.60 (1.84–17.05)','univariate ','N','0.002','cox','better\r'),(30000092,'27358498','DEFA1A3','DEFA1A3 CNV','','DEFA1A3','defensin alpha 1 and alpha 3, variable copy number locus',' ','','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','HR','3.69 (1.16–11.82)','multivariate','age, gender, proteinuria, hypertension, and serum creatinine at biopsy','0.028','cox','better\r'),(30000093,'26045217','NCX1','rs11893826','','SLC8A1','solute carrier family 8 member A1','AA/AG','','genotype','peripheral blood ','not mention','5′ nuclease allelic discrimination assays, with allele- speci c MGB probes','LN(55)','genotype ','AA/AG:GG','relapse during follow-up','N','Kaplan-Meier ','16.082','multivariate','therapeutic regimen used at induction',' < 0.001','log-rank test ','worse\r'),(30000094,'26045217','NCX1','rs434082','','SLC8A1','solute carrier family 8 member A1','GG','','genotype','peripheral blood ','not mention','5′ nuclease allelic discrimination assays, with allele- speci c MGB probes','LN(55)','genotype ','GG:AA/AG','sustained CR','N','Kaplan-Meier ','3.92','multivariate','the presence of hypertension ;the therapeutic regimen chosen at induction','0.048','log-rank test ','better\r'),(30000095,'24658608','MYH9 ','E1 haplotype','','MYH9','myosin heavy chain 9','GCCT','','genotype','peripheral blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','Kaplan-Meier ','N','univariate ','N','0.02','log-rank test ','worse\r'),(30000096,'24658608','MYH9 ','E1 haplotype','','MYH9','myosin heavy chain 9','GCCT','','genotype','peripheral blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','1.8 (1.1–2.9)','univariate ','N','0.02','cox','worse\r'),(30000097,'24658608','MYH9 ','E1 haplotype','','MYH9','myosin heavy chain 9','GCCT','','genotype','peripheral blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','2.0 (1.2–3.4)','multivariate','MDRD, hypertension ,african autossomal ancestry','0.01','cox','worse\r'),(30000098,'24658608','MYH9 ','rs3752462','','MYH9','myosin heavy chain 9','TC/TT','','genotype','peripheral blood','not mention','PCR','LN(196)','genotype ','TC/TT:CC','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','2.89 (1.31–6.36)','univariate ','N','0.008','cox','worse\r'),(30000099,'24658608','MYH9 ','rs3752462','','MYH9','myosin heavy chain 9','TC/TT','','genotype','peripheral blood','not mention','PCR','LN(196)','genotype ','TC/TT:CC','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','3.72 (1.47–9.38)','multivariate','MDRD, hypertension ,african autossomal ancestry','0.005','cox','worse\r'),(30000100,'14767013','ACE','ACE I/D（The 287 bp insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene）',' ','ACE','angiotensin I converting enzyme','DD+ID/aa+ab','','SNP','blood','not mention','PCR-RFLP ','MN(117)','genotype ','DD+ID/aa+ab: II/bb','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.028','log-rank test ','worse\r'),(30000101,'14767013','AII receptor 1','AT1R 1166A/C (The A/C transversion at base 1166 in the 3’untranslated region of the AT1R gene)',' ','AGTR1','angiotensin II receptor type 1','','','SNP','blood','not mention','PCR-RFLP ','MN(118)','genotype ','','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','','','\r'),(30000102,'14767013','AGT','AGT M235T(The C/T transition in exon 2 of the AGT gene)',' ','AGT','angiotensinogen ','TT+MT/aa+ab','','SNP','blood','not mention','PCR-RFLP ','MN(119)','genotype ','TT+MT/aa+ab:MM/bb','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','worse\r'),(30000103,'14767013','NOS','ecNOS4b/a(The 27 bp variable number of tandem repeats polymorphism in intron 4 of the ecNOS gene)',' ','NOS3','nitric oxide synthase 3','','','SNP','blood','not mention','PCR-RFLP ','MN(120)','genotype ','','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','','','\r'),(30000104,'20937089','PLA2R1 ','rs35771982/rs6757188',' ','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','genotype ','G:C','N','N','OR','1.900 (1.209–2.987)','univariate ','N','0.005','unconditional logistic regression','worse\r'),(30000105,'20937089','PLA2R1 ','rs6757188','','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','rs6757188 （T）+rs35771982 （G）','N','N','N','OR','1.647 (1.140–2.379)','univariate ','N','0.004','unconditional logistic regression','worse\r'),(30000106,'20937089','PLA2R1 ','rs6757188','','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','rs6757188 （T）+rs35771982 （C）','','N','N','OR','0.581 (0.368–0.919)','univariate ','N','0.004','unconditional logistic regression','better\r'),(30000107,'20937089','PLA2R1 ','rs35771982/rs6757188',' ','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','genotype  with or without the G allele','with:without','ESRF/death','N','Kaplan-Meier ','N','univariate ','N','0.74','log-rank test ','worse\r'),(30000108,'20937089','PLA2R1 ','rs35771982/rs6757188',' ','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','genotype  with or without the H1 haplotype','with:without','ESRF/death','N','Kaplan-Meier ','N','univariate ','N','0.77','log-rank test ','worse\r'),(30000109,'20937089','PLA2R1 ','rs35771982/rs6757188',' ','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','genotype  with or without the H3 haplotype','with:without','ESRF/death','N','Kaplan-Meier ','N','univariate ','N','0.7','log-rank test ','better\r'),(30000110,'24262501','PLA2R1 ','rs4664308','','PLA2R1','phospholipase A2 receptor 1','','','SNP','blood','not mention','TaqMan','IMN(89)','genotype ','GG/AG:AA','N','N','OR','2(1.23,3.23)','univariate ','N','0.005','N','worse\r'),(30000111,'24262501','HLA-DQA1','rs2187668','','HLA-DQA1','major histocompatibility complex, class II, DQ alpha 1','','','SNP','blood','not mention','TaqMan','IMN(89)','genotype ','AA/AG:GG','N','N','OR','3.7(2.256.08)','univariate ','N','<0.001 ','N','worse\r'),(30000112,'24262501','HLA-DQA1','rs2187668','','HLA-DQA1','major histocompatibility complex, class II, DQ alpha 1','','','SNP','blood','not mention','TaqMan','IMN(89)','genotype ','GG:AA/AG','doubling of serum creatinine','N','Kaplan-Meier ','N','univariate ','N','0.05','log-rank test ','worse\r'),(30000113,'24822208','urokinase gene','urokinase gene 3’-UTR T/C genotypes',' ','PLAU','plasminogen activator, urokinase','','','DNA','blood','not mention','PCR-RFLP ','IMN(91)','genotype ','CC:TC','doubling baseline serum creatinine (Cr) values or ESRD.','N','Kaplan-Meier ','N','univariate ','N','＞0.05（未具体写明）','log-rank test ','worse\r'),(30000114,'23964786','TLR9',' rs352139 ','','TLR9','toll like receptor 9','','','DNA','blood','not mention','TaqMan','MN(91)','genotype ','AA:GA/GG','developing MGN','N','OR','1.55 (1.02–2.35)','univariate ','N','0.04','logistic regression','worse\r'),(30000115,'23964786','TLR9','rs352140','','TLR9','toll like receptor 9','','','DNA','blood','not mention','TaqMan','MN(91)','genotype ','GG:GA/AA','developing MGN','N','OR','1.57 (1.03–2.39)','univariate ','N','0.034','logistic regression','worse\r'),(30000116,'23964786','TLR9',' rs352139 /rs352140',' ','TLR9','toll like receptor 9','','','DNA','blood','not mention','TaqMan','MN(91)','genotype ','A-G haplotype( rs352139 A and rs 352140 G):non A-G haplotype','probability of patient survival','N','Kaplan-Meier ','N','univariate ','N','0.38','log-rank test ','\r'),(30000117,'23964786','TLR9',' rs352139 /rs352140',' ','TLR9','toll like receptor 9','','','DNA','blood','not mention','TaqMan','MN(91)','genotype ','A-G haplotype( rs352139 A and rs 352140 G):non A-G haplotype','probability of renal survival','N','Kaplan-Meier ','N','univariate ','N','0.944','log-rank test ','\r'),(30000118,'17213876','TNFA','TNFA2','',' tnfa','tumor necrosis factor a','','','DNA','blood','not mention','PCR-RFLP ','MN(100)','genotype ','A1A1：A2A2/A1A2','ESRF/death or CRF','N','Kaplan-Meier ','N','univariate ','N','＞0.05（未具体写明）','log-rank test ','\r'),(30000119,'17213876','TNFd','TNFd2 ','','TNF','tumor necrosis factor','','','DNA','blood','not mention','PCR-RFLP ','MN(100)','genotype ','d2 allele: non d2 allele','ESRF/death or CRF','N','Kaplan-Meier ','N','univariate ','N','＞0.05（未具体写明）','','\r'),(30000120,'18495745','SERPINE1','PAI-1','','SERPINE1','serpin family E member 1','','','DNA','blood','not mention','allele specific PCR','MN(104)','genotype ','4G4G:4G5G:5G5G','ESRF','N','Kaplan-Meier ','N','univariate ','N','0.52','log-rank test ','worse\r'),(30000121,'18495745','SERPINE1','PAI-1','','SERPINE1','serpin family E member 1','','','DNA','blood','not mention','allele specific PCR','MN(104)','genotype ','4G4G:4G5G:5G5G','death','N','Kaplan-Meier ','N','univariate ','N','0.811','log-rank test ','worse\r'),(30000122,'15200436','IL-10','G-1082A','','IL-10','Interleukin 10','GG','','SNP','\"Whole blood',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(30000123,'15200436','IL-10','G-1082A','','IL-10','Interleukin 10','GG','','SNP','\"Whole blood',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(30000124,'21777344','CYP11B2','C-344T','','CYP11B2','Cytochrome P450 Family 11 Subfamily B Member 2 ','TT','','SNP','whole blood samples','not mention','PCR','FSGS(81)','genotype ','TT:CC/CT','stage V of chronic kidney disease','N','Kaplan–Meier method','N','univariate ','N','0.027','log-rank test (Mantel-Cox)','better\r'),(30000125,'21997394','APOL1','G1,G2','','APOL1','Apolipoprotein L1','G1G1','','SNP','whole blood samples','not mention','TaqMan assays ','FSGS(92)','genotype ','G1G1:G1G2/G2G2','ESRD','N','Kaplan-Meier','N','univariate ','N','＜0.01','log-rank test (Mantel-Cox)','worse\r'),(30000126,'25573908','APOL1','G1,G2','','APOL1','Apolipoprotein L1','G1,G2','','SNP','whole blood samples','not mention','Taqman assay','FSGS(138)','genotype ','G1G1:G1G2/G2G2','ESRD','N','Kaplan-Meier','N','univariate ','N','0.002','log-rank test (Mantel-Cox)','worse\r'),(30000127,'19546528','ACE ,eNOS','Angiotensin-converting enzyme (ACE) I/D polymorphism ,eNOS G894T Gene Variants',' ','ACE,NOS3','angiotensin I converting enzyme,nitric oxide synthase 3','DD,GG','','SNP','blood','not mention','PCR,electrophoresed through an agarose gel.','IgAN(64)','genotype(ACE I/D + eNOS G894T)','(DD+GG):other','30% decrease of creatinine clearance ','N','HR','8.4(2.45–29.10)','multivariate','Baseline MAP','0.001','cox','worse\r'),(30000128,'19546528','ACE ,eNOS','Angiotensin-converting enzyme (ACE) I/D polymorphism ,eNOS G894T Gene Variants',' ','ACE,NOS3','angiotensin I converting enzyme,nitric oxide synthase 3','DD,GG','','SNP','blood','not mention','PCR,electrophoresed through an agarose gel.','IgAN(64)','genotype(ACE I/D + eNOS G894T)','(DD+GG):other','30% decrease of creatinine clearance ','N','HR','5.9(1.98–17.76)','univariate ','N','0.001','cox','worse\r'),(30000129,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ,rs1042032 ','','EPHX2','epoxide hydrolase 2','A,G','rs751141,rs1042032 ','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.45 (0.29–0.71)','univariate ','N','＜0.001','cox','better\r'),(30000130,'21429967','epoxide hydrolase (EPHX2)','rs751141 (R287Q; G＞A) ,rs1042032 ','','EPHX2','epoxide hydrolase 2','A,G','rs751141,rs1042032 ','SNP','peripheral blood mononuclear cells','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.45 (0.29–0.71)','multivariate','age,gender ','＜0.001','cox','better\r'),(30000131,'19357720','C1GALT1,ST6GALNAC2  ','YATIG, YAGDA, YATDG,OTHERS,ADG ,OTHERS',' ','C1GALT1,ST6GALNAC2','core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1,ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2','YATIG, YAGDA, YATDG,OTHERS,ADG ,OTHERS',' ','Haplotype ','blood','not mention','PCR, sequence','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.52 (0.32–0.84)','multivariate','age, gender, hypertension, diabetes mellitus, initial proteinuria','0.001','cox','better\r'),(30000132,'12911556','angiotensinogen gene (AGT) ','AGT A(-20)C,AGT M235T','in the 5 upstream region of the core promoter in the AGT gene,exon 2 ','AGT','angiotensinogen','C,T','','','','','','IgAN[with follow-up data were recruited for renal survival analysis](119)','haplotype (C1GALT1 ※ ST6GALNAC2 )  ','ATDG (C1GALT1) * ADG (ST6GALNAC2) :ATIG (C1GALT1) * Others (ST6GALNAC2)/ATIG (C1GALT1) * ADG (ST6GAL','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.022','log-rank test ','worse\r');

--
-- Table structure for table `sur`
--

CREATE TABLE `sur` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `uniprot` varchar(100) DEFAULT NULL,
  `descript` varchar(1000) DEFAULT NULL,
  `moltype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  `ckd` varchar(100) DEFAULT NULL,
  `expression` varchar(100) DEFAULT NULL,
  `HPAcells_in_glomeruli` varchar(500) DEFAULT NULL,
  `evidenceG` varchar(500) DEFAULT NULL,
  `cells_in_tubules` varchar(500) DEFAULT NULL,
  `evidenceT` varchar(500) DEFAULT NULL,
  `source_HPA` varchar(500) DEFAULT NULL,
  `Gene_descriptioni` varchar(500) DEFAULT NULL,
  `Protein_classi` varchar(500) DEFAULT NULL,
  `Predicted_localizationi_HPA` varchar(500) DEFAULT NULL,
  `Number_of_transcriptsi` varchar(500) DEFAULT NULL,
  `RNA_tissue_categoryi` varchar(500) DEFAULT NULL,
  `Protein_evidencei` varchar(500) DEFAULT NULL,
  `Protein_expressioni` varchar(500) DEFAULT NULL,
  `RNA_expression_TPMi_Protein_expression_scoreI` varchar(500) DEFAULT NULL,
  `Gene_name` varchar(500) DEFAULT NULL,
  `Chromosome` varchar(500) DEFAULT NULL,
  `Cytoband` varchar(500) DEFAULT NULL,
  `UniProt_hpa` varchar(500) DEFAULT NULL,
  `Drug_IDs_drugbank` varchar(500) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `sur`
--



--
-- Table structure for table `surbk`
--

CREATE TABLE `surbk` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `uniprot` varchar(100) DEFAULT NULL,
  `descript` varchar(1000) DEFAULT NULL,
  `moltype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  `ckd` varchar(100) DEFAULT NULL,
  `expression` varchar(100) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `surbk`
--




